

10/513699

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaeal1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified
prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new
custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days
of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current
U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom
IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental
spectra
NEWS 16 MAR 31 CA/CAPLUS and CASREACT patent number format for U.S.
applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new
predefined hit display formats
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

<12/04/2007>

Erich Leese

10/513699

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:31:08 ON 27 MAY 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:31:16 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

DICTIONARY FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10550641Ex222.str

10/513699



```
chain nodes :
22 23 24 26 27 28 29 31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-35 2-34 3-33 4-32 5-8 6-36 7-31 12-15 13-28 14-29 17-22 22-23 22-24
24-26 24-27 36-37 37-38 37-39 37-40
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
exact/norm bonds :
1-35 2-34 3-33 4-32 6-36 7-31 13-28 14-29 22-23 22-24 24-26 24-27 36-37

exact bonds :
5-8 12-15 17-22 37-38 37-39 37-40
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 7 : 13 :
```

G1:C,N

G2:C,H

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 22:CLASS
23:CLASS 24:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
```

<12/04/2007>

Erich Leese


10/513699

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

G2 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 14:31:40 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 177 TO ITERATE

100.0% PROCESSED 177 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L2 1 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 14:31:44 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

<12/04/2007>

Erich Leese

10/513699

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 May 2008 VOL 148 ISS 22
FILE LAST UPDATED: 26 May 2008 (20080526/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l2 full

L3 1 L2

=> d ibib abs hitstr

10/513699

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:817651 CAPLUS

DOCUMENT NUMBER: 141:332206

TITLE: Preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers

INVENTOR(S): Chakravarty, Prasun K.; Fisher, Michael H.; Parsons, William H.; Liang, Jun; Zhou, Bishan

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004084824	A2	20041007	WO 2004-US8532	20040319
WO 2004084824	A3	20050331		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004224392	A1	20041007	AU 2004-224392	20040319
CA 2519677	A1	20041007	CA 2004-2519677	20040319
EP 1608622	A2	20051228	EP 2004-757920	20040319
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
CN 1791580	A	20060621	CN 2004-80013599	20040319
JP 2006521357	T	20060921	JP 2006-507395	20040319
IN 2005DN04098	A	20070831	IN 2005-DN4098	20050912
US 20060293339	A1	20061228	US 2005-550641	20050923
PRIORITY APPLN. INFO.:			US 2003-456312P	P 20030324
			WO 2004-US8532	A 20040319

OTHER SOURCE(S): MARPAT 141:332206

GI



AB The title biaryl substituted pyridine, pyrimidine and pyrazine compds. [I or II; H-1 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; H-2 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; R4, R5 = H, alkyl, alkoxy, aryloxy, etc.; R6-R8 = H, alkyl, cycloalkyl, alkoxy, etc.] which are sodium channel blockers useful for the treatment of pain (no data), were prepared E.g., a 2-step synthesis of III, starting from 2-bromo-6-methylpyridine and 3-bromophenylboronic acid, was given. Claimed pharmaceutical compns. comprise an effective amount of the instant compds. I, either alone, or in combination with one or more therapeutically active compds., and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compds., either alone, or in combination with one or more other therapeutically active compds.


IT 770725-39-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers for treatment or prevention of pain)

RN 770725-39-8 CAPLUS

CN [4,4'-Bipyrimidine]-2-carboxamide, 6'-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



10/513699

<12/04/2007>

Erich Leese

10/513699

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

12.65

191.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.80

-0.80

FILE 'REGISTRY' ENTERED AT 14:40:38 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

DICTIONARY FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10550641election.str

10/513699



```
ring nodes :
1  2  3  4  5  6  7  8  9  10 11 12 13 14 15 16 17 18
chain bonds :
5-8 12-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
exact/norm bonds :
5-8 7-8 7-12 8-9 9-10 10-11 11-12 12-15 13-14 13-18 14-15 15-16 16-17
17-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 7 : 13 :
```

G1:C,N

G2:C,H

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L4 STRUCTURE UPLOADED

=> d 14


L4 HAS NO ANSWERS

L4 STR

<12/04/2007>

Erich Leese

10/513699



G1 C,N

G2 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s 14 full

FULL SEARCH INITIATED 14:40:57 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2127961 TO ITERATE

47.0% PROCESSED 1000000 ITERATIONS

18557 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.08

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**

PROJECTED ITERATIONS: 2127961 TO 2127961

PROJECTED ANSWERS: 38892 TO 40084

L5 18557 SEA SSS FUL L4

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

178.36	369.58
--------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

0.00	-0.80
------	-------

FILE 'CAPLUS' ENTERED AT 14:41:12 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

10/513699

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 May 2008 VOL 148 ISS 22
FILE LAST UPDATED: 26 May 2008 (20080526/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l5 full
L6 2451 L5

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	4.80	374.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.80

FILE 'REGISTRY' ENTERED AT 14:46:54 ON 27 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1
DICTIONARY FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10550641claim43.str

10/513699



chain nodes :
24 25 26 27 28 29 30 31 32 33 34 35 36 38 39 40 41 42 43
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-43 2-42 3-41 4-40 5-8 6-24 9-39 10-38 11-36 12-15 13-29 14-35 17-30
24-25 25-26 25-27 25-28 29-33 29-34 30-31 30-32
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
exact/norm bonds :
1-43 2-42 3-41 4-40 6-24 9-39 10-38 11-36 13-29 14-35 17-30 24-25 29-33
29-34 30-31 30-32
exact bonds :
5-8 12-15 25-26 25-27 25-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 7 : 13 :

G1:C,N

G2:C,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS
42:CLASS 43:CLASS

<12/04/2007>

Erich Leese


10/513699

L7 STRUCTURE UPLOADED

=> d 17

L7 HAS NO ANSWERS

L7 STR



G1 C,N

G2 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s 17 full

FULL SEARCH INITIATED 14:47:16 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 42 TO ITERATE

100.0% PROCESSED 42 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L8 1 SEA SSS FUL L7

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

552.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-0.80

FILE 'CAPLUS' ENTERED AT 14:47:19 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

<12/04/2007>

Erich Leese

10/513699

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 May 2008 VOL 148 ISS 22
FILE LAST UPDATED: 26 May 2008 (20080526/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

```
=> s l8 full
L9          1 L8

=> d ibib abs hitstr
```

10/513699

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:817651 CAPLUS

DOCUMENT NUMBER: 141:332206

TITLE: Preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers

INVENTOR(S): Chakravarty, Prasun K.; Fisher, Michael H.; Parsons, William H.; Liang, Jun; Zhou, Bishan

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004084824	A2	20041007	WO 2004-US8532	20040319
WO 2004084824	A3	20050331		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004224392	A1	20041007	AU 2004-224392	20040319
CA 2519677	A1	20041007	CA 2004-2519677	20040319
EP 1608622	A2	20051228	EP 2004-757920	20040319
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
CN 1791580	A	20060621	CN 2004-80013599	20040319
JP 2006521357	T	20060921	JP 2006-507395	20040319
IN 2005DN04098	A	20070831	IN 2005-DN4098	20050912
US 20060293339	A1	20061228	US 2005-550641	20050923
PRIORITY APPLN. INFO.:			US 2003-456312P	P 20030324
			WO 2004-US8532	A 20040319

OTHER SOURCE(S): MARPAT 141:332206

GI



AB The title biaryl substituted pyridine, pyrimidine and pyrazine compds. [I or II; H-1 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; H-2 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; R4, R5 = H, alkyl, alkoxy, aryloxy, etc.; R6-R8 = H, alkyl, cycloalkyl, alkoxy, etc.] which are sodium channel blockers useful for the treatment of pain (no data), were prepared E.g., a 2-step synthesis of III, starting from 2-bromo-6-methylpyridine and 3-bromophenylboronic acid, was given. Claimed pharmaceutical compns. comprise an effective amount of the instant compds. I, either alone, or in combination with one or more therapeutically active compds., and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compds., either alone, or in combination with one or more other therapeutically active compds.


IT 770726-82-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers for treatment or prevention of pain)

RN 770726-82-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



10/513699

<12/04/2007>

Erich Leese

10/513699

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

7.37

560.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.80

-1.60

FILE 'REGISTRY' ENTERED AT 14:50:00 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

DICTIONARY FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10550641claim39.str



<12/04/2007>

Erich Leese

10/513699

chain nodes :
24 25 26 28 29 30 31 32 34 35 36
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-32 2-31 3-30 4-29 5-8 6-24 7-36 9-28 11-26 12-15 13-35 14-25 17-34
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
exact/norm bonds :
1-32 2-31 3-30 4-29 7-36 9-28 11-26 13-35 14-25
exact bonds :
5-8 6-24 12-15 17-34
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 7 : 13 :

G1:C,N

G2:C,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 24:CLASS
25:CLASS 26:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 34:CLASS
35:CLASS 36:CLASS

L10 STRUCTURE UPLOADED

=> s l10 full
FULL SEARCH INITIATED 14:50:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1417 TO ITERATE

100.0% PROCESSED 1417 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L11 0 SEA SSS FUL L10

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	180.20	740.31
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.60

FILE 'REGISTRY' ENTERED AT 14:52:48 ON 27 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

<12/04/2007>

Erich Leese

10/513699

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1
DICTIONARY FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10550641claim40.str



chain nodes :
24 25 27 28 29 30 31 33 34 35 36 37
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-31 2-30 3-29 4-28 5-8 6-24 7-35 9-27 10-36 11-25 12-15 13-34 17-33
18-37
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
exact/norm bonds :

<12/04/2007>

Erich Leese

10/513699

1-31 2-30 3-29 4-28 6-24 7-35 9-27 10-36 11-25 13-34 18-37
exact bonds :
5-8 12-15 17-33
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 7 : 13 :

G1:C,N

G2:C,H

G3:C,O

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 24:CLASS
25:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 33:CLASS 34:CLASS
35:CLASS 36:CLASS 37:CLASS

L12 STRUCTURE UPLOADED

=> d 112

L12 HAS NO ANSWERS

L12 STR



G1 C,N

G2 C,H

G3 C,O

Structure attributes must be viewed using STN Express query preparation.

<12/04/2007>

Erich Leese

10/513699

=> s l12 full

FULL SEARCH INITIATED 14:57:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4667 TO ITERATE

100.0% PROCESSED 4667 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

L13 6 SEA SSS FUL L12

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	182.04	922.35
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.60

FILE 'CAPLUS' ENTERED AT 14:57:55 ON 27 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 May 2008 VOL 148 ISS 22
FILE LAST UPDATED: 26 May 2008 (20080526/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l13 full

L14 1 L13

=> d ibib abs hitstr tot

10/513699

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:817651 CAPLUS

DOCUMENT NUMBER: 141:332206

TITLE: Preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers

INVENTOR(S): Chakravarty, Prasun K.; Fisher, Michael H.; Parsons, William H.; Liang, Jun; Zhou, Bishan

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004084824	A2	20041007	WO 2004-US8532	20040319
WO 2004084824	A3	20050331		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004224392	A1	20041007	AU 2004-224392	20040319
CA 2519677	A1	20041007	CA 2004-2519677	20040319
EP 1608622	A2	20051228	EP 2004-757920	20040319
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
CN 1791580	A	20060621	CN 2004-80013599	20040319
JP 2006521357	T	20060921	JP 2006-507395	20040319
IN 2005DN04098	A	20070831	IN 2005-DN4098	20050912
US 20060293339	A1	20061228	US 2005-550641	20050923
PRIORITY APPLN. INFO.:			US 2003-456312P	P 20030324
			WO 2004-US8532	A 20040319

OTHER SOURCE(S): MARPAT 141:332206

GI



AB The title biaryl substituted pyridine, pyrimidine and pyrazine compds. [I or II; H-1 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; H-2 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; R4, R5 = H, alkyl, alkoxy, aryloxy, etc.; R6-R8 = H, alkyl, cycloalkyl, alkoxy, etc.] which are sodium channel blockers useful for the treatment of pain (no data), were prepared E.g., a 2-step synthesis of III, starting from 2-bromo-6-methylpyridine and 3-bromophenylboronic acid, was given. Claimed pharmaceutical compns. comprise an effective amount of the instant compds. I, either alone, or in combination with one or more therapeutically active compds., and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compds., either alone, or in combination with one or more other therapeutically active compds.


IT 770725-53-6P 770725-54-7P 770725-55-8P
770725-56-9P 770725-57-0P 770725-58-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers for treatment or prevention of pain)

RN 770725-53-6 CAPLUS


CN Pyrimidine, 4-methyl-2-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



10/513699


RN 770725-54-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770725-55-8 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770725-56-9 CAPLUS

CN Pyrimidine, 4-methyl-2-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA
INDEX NAME)



RN 770725-57-0 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)



RN 770725-58-1 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)

10/513699



<12/04/2007>

Erich Leese

10/513699

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

8.81

931.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.80

-2.40

FILE 'REGISTRY' ENTERED AT 15:01:51 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

DICTIONARY FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10550641claim38.str

10/513699



```
chain nodes :
24 25 27 28 29 30 31 33 34 35 37 38 39 40 41
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-31 2-30 3-29 4-28 5-8 6-24 9-27 10-35 11-25 12-15 13-34 14-41 17-33
24-37 37-38 37-39 37-40
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
exact/norm bonds :
1-31 2-30 3-29 4-28 6-24 9-27 10-35 11-25 13-34 14-41 24-37
exact bonds :
5-8 12-15 17-33 37-38 37-39 37-40
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 7 : 13 :
```

G1:C,N

G2:C,H

G3:C,O

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 24:CLASS
25:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 33:CLASS 34:CLASS
35:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS
```

<12/04/2007>

Erich Leese


10/513699

L15 STRUCTURE UPLOADED

=> d 115

L15 HAS NO ANSWERS

L15 STR



G1 C,N

G2 C,H

G3 C,O

Structure attributes must be viewed using STN Express query preparation.

=> s 115 full

FULL SEARCH INITIATED 15:04:10 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1526 TO ITERATE

100.0% PROCESSED 1526 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

L16 4 SEA SSS FUL L15

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

179.74

1110.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-2.40

<12/04/2007>

Erich Leese

10/513699

FILE 'CAPLUS' ENTERED AT 15:04:15 ON 27 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 May 2008 VOL 148 ISS 22
FILE LAST UPDATED: 26 May 2008 (20080526/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l16 full
L17 1 L16

=> d ibib abs hitstr tot

10/513699

L17 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:817651 CAPLUS

DOCUMENT NUMBER: 141:332206

TITLE: Preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers

INVENTOR(S): Chakravarty, Prasun K.; Fisher, Michael H.; Parsons, William H.; Liang, Jun; Zhou, Bishan

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004084824	A2	20041007	WO 2004-US8532	20040319
WO 2004084824	A3	20050331		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004224392	A1	20041007	AU 2004-224392	20040319
CA 2519677	A1	20041007	CA 2004-2519677	20040319
EP 1608622	A2	20051228	EP 2004-757920	20040319
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
CN 1791580	A	20060621	CN 2004-80013599	20040319
JP 2006521357	T	20060921	JP 2006-507395	20040319
IN 2005DN04098	A	20070831	IN 2005-DN4098	20050912
US 20060293339	A1	20061228	US 2005-550641	20050923
PRIORITY APPLN. INFO.:			US 2003-456312P	P 20030324
			WO 2004-US8532	A 20040319


OTHER SOURCE(S): MARPAT 141:332206

GI




- AB The title biaryl substituted pyridine, pyrimidine and pyrazine compds. [I or II; H-1 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; H-2 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; R4, R5 = H, alkyl, alkoxy, aryloxy, etc.; R6-R8 = H, alkyl, cycloalkyl, alkoxy, etc.] which are sodium channel blockers useful for the treatment of pain (no data), were prepared E.g., a 2-step synthesis of III, starting from 2-bromo-6-methylpyridine and 3-bromophenylboronic acid, was given. Claimed pharmaceutical compns. comprise an effective amount of the instant compds. I, either alone, or in combination with one or more therapeutically active compds., and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compds., either alone, or in combination with one or more other therapeutically active compds.
- IT 770725-40-1P 770725-41-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers for treatment or prevention of pain)
- RN 770725-40-1 CAPLUS
- CN Pyrimidine, 2-methyl-4-[6-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]- (CA INDEX NAME)


10/513699



RN 770725-41-2 CAPLUS
CN 2-Pyrimidinecarboxylic acid, 4-[6-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]- (CA INDEX NAME)



IT 770725-42-3P 770727-22-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers for treatment or prevention of pain)
RN 770725-42-3 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[6-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]- (CA INDEX NAME)




RN 770727-22-5 CAPLUS

<12/04/2007>

Erich Leese

10/513699

CN 2-Pyrimidinecarboxylic acid, 4-[6-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]-, methyl ester (CA INDEX NAME)



<12/04/2007>

Erich Leese

10/513699

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

7.85

1118.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.80

-3.20

FILE 'REGISTRY' ENTERED AT 15:07:32 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

DICTIONARY FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10550641claim37.str

10/513699



```
chain nodes :
24 25 26 27 28 30 31 32 34
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-28 2-27 3-26 4-25 5-8 6-24 10-32 12-15 13-31 14-34 17-30
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
exact/norm bonds :
1-28 2-27 3-26 4-25 6-24 10-32 13-31 14-34
exact bonds :
5-8 12-15 17-30
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 7 : 13 :
```

G1:C,N

G2:C,H

G3:C,O

Match level :

```
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:CLASS 30:CLASS 31:CLASS 32:CLASS 34:CLASS
```

10/513699

L18 STRUCTURE UPLOADED

=> s l18 full
FULL SEARCH INITIATED 15:07:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 395 TO ITERATE

100.0% PROCESSED 395 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

L19 7 SEA SSS FUL L18

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	178.82	1297.57
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-3.20

FILE 'CAPLUS' ENTERED AT 15:08:44 ON 27 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 May 2008 VOL 148 ISS 22
FILE LAST UPDATED: 26 May 2008 (20080526/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l19 full
L20 1 L19

=> d ibib abs hitstr tot

10/513699

L20 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:817651 CAPLUS

DOCUMENT NUMBER: 141:332206

TITLE: Preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers

INVENTOR(S): Chakravarty, Prasun K.; Fisher, Michael H.; Parsons, William H.; Liang, Jun; Zhou, Bishan

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004084824	A2	20041007	WO 2004-US8532	20040319
WO 2004084824	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004224392	A1	20041007	AU 2004-224392	20040319
CA 2519677	A1	20041007	CA 2004-2519677	20040319
EP 1608622	A2	20051228	EP 2004-757920	20040319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1791580	A	20060621	CN 2004-80013599	20040319
JP 2006521357	T	20060921	JP 2006-507395	20040319
IN 2005DN04098	A	20070831	IN 2005-DN4098	20050912
US 20060293339	A1	20061228	US 2005-550641	20050923
PRIORITY APPLN. INFO.:			US 2003-456312P	P 20030324
			WO 2004-US8532	A 20040319

OTHER SOURCE(S): MARPAT 141:332206

GI




- AB The title biaryl substituted pyridine, pyrimidine and pyrazine compds. [I or II; H-1 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; H-2 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; R4, R5 = H, alkyl, alkoxy, aryloxy, etc.; R6-R8 = H, alkyl, cycloalkyl, alkoxy, etc.] which are sodium channel blockers useful for the treatment of pain (no data), were prepared E.g., a 2-step synthesis of III, starting from 2-bromo-6-methylpyridine and 3-bromophenylboronic acid, was given. Claimed pharmaceutical compns. comprise an effective amount of the instant compds. I, either alone, or in combination with one or more therapeutically active compds., and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compds., either alone, or in combination with one or more other therapeutically active compds.
- IT 770725-35-4P 770725-36-5P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers for treatment or prevention of pain)
- RN 770725-35-4 CAPLUS
- CN [4,4'-Bipyrimidine]-2-carboxylic acid, 6'-[2-(trifluoromethyl)phenyl]-, methyl ester (CA INDEX NAME)




10/513699


RN 770725-36-5 CAPLUS
CN [4,4'-Bipyrimidine]-2-carboxamide, 6'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 770725-34-3P 770725-37-6P 770725-38-7P
770725-39-8P 770727-21-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers for treatment or prevention of pain)
RN 770725-34-3 CAPLUS
CN 4,4'-Bipyrimidine, 2-methyl-6'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 770725-37-6 CAPLUS
CN 4,4'-Bipyrimidine, 2-methyl-6'-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 770725-38-7 CAPLUS
CN [4,4'-Bipyrimidine]-2-carboxylic acid, 6'-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/513699




RN 770725-39-8 CAPLUS

CN [4,4'-Bipyrimidine]-2-carboxamide, 6'-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 770727-21-4 CAPLUS

CN [4,4'-Bipyrimidine]-2-carboxylic acid, 6'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



10/513699

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

16.97

1314.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.80

-4.00

FILE 'REGISTRY' ENTERED AT 15:23:16 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

DICTIONARY FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10550641claim36.str



<12/04/2007>

Erich Leese

10/513699

```
chain nodes :
24 25 26 27 28 30 31 34
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-28 2-27 3-26 4-25 5-8 6-24 12-15 13-31 14-34 17-30
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
exact/norm bonds :
1-28 2-27 3-26 4-25 6-24 13-31 14-34
exact bonds :
5-8 12-15 17-30
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 7 : 13 :
```

G1:C,N

G2:C,H

G3:C,O

G4:C,H,O,Cl,Br,F,I,At

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:CLASS 30:CLASS 31:CLASS 34:CLASS
```


L21 STRUCTURE UPLOADED

=> d 121

L21 HAS NO ANSWERS

L21 STR

10/513699



G1 C,N

G2 C,H

G3 C,O

G4 C,H,O,Cl,Br,F,I,At

Structure attributes must be viewed using STN Express query preparation.

=> s l21 full

FULL SEARCH INITIATED 15:23:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 9106 TO ITERATE

100.0% PROCESSED 9106 ITERATIONS

110 ANSWERS

SEARCH TIME: 00.00.01

L22 110 SEA SSS FUL L21

=> file capluis

'CAPLUIS' IS NOT A VALID FILE NAME

SESSION CONTINUES IN FILE 'REGISTRY'

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

1492.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-4.00

FILE 'CAPLUS' ENTERED AT 15:23:55 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

<12/04/2007>

Erich Leese

10/513699

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 May 2008 VOL 148 ISS 22
FILE LAST UPDATED: 26 May 2008 (20080526/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 122 full
L23 1 L22

=> d ibib abs hitstr tot

10/513699

L23 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:817651 CAPLUS

DOCUMENT NUMBER: 141:332206

TITLE: Preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers

INVENTOR(S): Chakravarty, Prasun K.; Fisher, Michael H.; Parsons, William H.; Liang, Jun; Zhou, Bishan

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004084824	A2	20041007	WO 2004-US8532	20040319
WO 2004084824	A3	20050331		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004224392	A1	20041007	AU 2004-224392	20040319
CA 2519677	A1	20041007	CA 2004-2519677	20040319
EP 1608622	A2	20051228	EP 2004-757920	20040319
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
CN 1791580	A	20060621	CN 2004-80013599	20040319
JP 2006521357	T	20060921	JP 2006-507395	20040319
IN 2005DN04098	A	20070831	IN 2005-DN4098	20050912
US 20060293339	A1	20061228	US 2005-550641	20050923
PRIORITY APPLN. INFO.:			US 2003-456312P	P 20030324
			WO 2004-US8532	A 20040319

OTHER SOURCE(S): MARPAT 141:332206

GI




- AB The title biaryl substituted pyridine, pyrimidine and pyrazine compds. [I or II; H-1 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; H-2 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; R4, R5 = H, alkyl, alkoxy, aryloxy, etc.; R6-R8 = H, alkyl, cycloalkyl, alkoxy, etc.] which are sodium channel blockers useful for the treatment of pain (no data), were prepared E.g., a 2-step synthesis of III, starting from 2-bromo-6-methylpyridine and 3-bromophenylboronic acid, was given. Claimed pharmaceutical compns. comprise an effective amount of the instant compds. I, either alone, or in combination with one or more therapeutically active compds., and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compds., either alone, or in combination with one or more other therapeutically active compds.
- IT 770723-58-5P 770723-59-6P 770724-99-7P
770725-00-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers for treatment or prevention of pain)
- RN 770723-58-5 CAPLUS
- CN Pyrimidine, 2-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



10/513699


RN 770723-59-6 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770724-99-7 CAPLUS

CN Pyrimidine, 4-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770725-00-3 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



IT 770723-60-9P 770723-70-1P 770723-71-2P
770723-72-3P 770723-73-4P 770723-74-5P
770723-75-6P 770723-76-7P 770723-77-8P
770723-78-9P 770723-79-0P 770723-80-3P
770723-81-4P 770723-82-5P 770723-83-6P
770723-84-7P 770723-85-8P 770723-86-9P
770723-87-0P 770723-88-1P 770723-89-2P
770723-90-5P 770723-91-6P 770723-92-7P
770723-93-8P 770723-94-9P 770723-98-3P
770724-00-0P 770724-01-1P 770724-06-6P
770724-11-3P 770724-12-4P 770724-13-5P
770724-14-6P 770724-15-7P 770724-16-8P
770724-17-9P 770724-18-0P 770724-22-6P
770724-23-7P 770724-24-8P 770724-25-9P
770724-33-9P 770724-34-0P 770724-35-1P
770724-36-2P 770724-37-3P 770724-38-4P
770724-39-5P 770724-40-8P 770724-41-9P
770724-42-0P 770724-43-1P 770724-44-2P
770724-51-1P 770724-54-4P 770724-58-8P


770724-59-9P 770724-60-2P 770724-62-4P
 770724-63-5P 770724-64-6P 770724-65-7P
 770724-68-0P 770724-78-2P 770724-79-3P
 770724-83-9P 770724-84-0P 770724-85-1P
 770724-86-2P 770724-97-5P 770725-01-4P
 770725-02-5P 770725-03-6P 770725-04-7P
 770725-05-8P 770725-06-9P 770725-07-0P
 770725-08-1P 770725-09-2P 770725-10-5P
 770725-11-6P 770725-12-7P 770725-13-8P
 770725-14-9P 770725-15-0P 770725-16-1P
 770725-17-2P 770725-18-3P 770725-19-4P
 770725-20-7P 770725-21-8P 770725-22-9P
 770725-23-0P 770725-24-1P 770725-25-2P
 770725-26-3P 770725-27-4P 770725-28-5P
 770725-29-6P 770725-30-9P 770725-31-0P
 770725-32-1P 770725-33-2P 770727-16-7P
 770727-17-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of biaryl substituted 6-membered heterocycles as sodium channel
 blockers for treatment or prevention of pain)


RN 770723-60-9 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-
 (CA INDEX NAME)



RN 770723-70-1 CAPLUS


CN 2-Pyrimidinecarboxamide, N-methoxy-N-methyl-4-[2'-(trifluoromethoxy)[1,1'-
 biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-71-2 CAPLUS


CN Methanone, 4-morpholinyl[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-
 pyrimidinyl]- (CA INDEX NAME)

10/513699




RN 770723-72-3 CAPLUS

CN Ethanone, 1-[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]-
(CA INDEX NAME)




RN 770723-73-4 CAPLUS

CN Alanine, 2-methyl-N-[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]carbonyl]-, methyl ester
(CA INDEX NAME)



RN 770723-74-5 CAPLUS


CN 2-Pyrimidinecarboxamide, N-(2-cyanoethyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)



RN 770723-75-6 CAPLUS


CN Alanine, 2-methyl-N-[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]carbonyl]-
(CA INDEX NAME)

10/513699




RN 770723-76-7 CAPLUS

CN 2-Pyrimidinecarboxamide, N-(2-amino-1,1-dimethyl-2-oxoethyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-77-8 CAPLUS

CN Methanone, 1-piperazinyl[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 770723-78-9 CAPLUS


CN 2-Pyrimidinecarboxamide, N-2H-tetrazol-5-yl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-79-0 CAPLUS


CN Cyclopropanecarboxylic acid, 1-[[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)

10/513699




RN 770723-80-3 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]carbonyl]amino]- (CA INDEX NAME)




RN 770723-81-4 CAPLUS

CN 2-Pyrimidinecarboxamide, N-[1-(aminocarbonyl)cyclopropyl]-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-82-5 CAPLUS


CN 2-Pyrimidinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-83-6 CAPLUS


CN 2-Pyrimidinecarboxamide, N-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770723-84-7 CAPLUS

CN 2-Pyrimidinecarboxamide, N,N-dimethyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-85-8 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



RN 770723-86-9 CAPLUS

CN 2-Pyrimidinecarboxamide, N-[(1S)-2-amino-1-methyl-2-oxoethyl]-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 770723-87-0 CAPLUS

<12/04/2007>

Erich Leese


10/513699

CN 2-Pyrimidinecarboxamide, N-[2-(1-piperidinyl)ethyl]-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-88-1 CAPLUS


CN 2-Pyrimidinecarboxamide, N-(1,1-dimethylethyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-89-2 CAPLUS

CN 2-Pyrimidinecarboxamide, N-[(1R)-2-amino-1-methyl-2-oxoethyl]-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 770723-90-5 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]carbonyl]- (CA INDEX NAME)

10/513699




RN 770723-91-6 CAPLUS

CN Pyrimidine, 2,5-dimethyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)



RN 770723-92-7 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 5-methyl-4-[2'-(trifluoromethoxy)[1,1'-
biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-93-8 CAPLUS


CN 2-Pyrimidinecarboxamide, 5-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-
3-yl]- (CA INDEX NAME)

10/513699




RN 770723-94-9 CAPLUS

CN 2-Pyrimidinecarboxamide, N-(2-amino-2-oxoethyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-98-3 CAPLUS

CN Pyrimidine, 2-methyl-4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-00-0 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-01-1 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770724-06-6 CAPLUS

CN 2-Pyrimidinecarbonitrile, 4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770724-11-3 CAPLUS

CN Pyrimidine, 4-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2-methyl-
(CA INDEX NAME)



RN 770724-12-4 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)



RN 770724-13-5 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)

10/513699




RN 770724-14-6 CAPLUS

CN 2-Pyrimidinecarboxamide, N-(2-amino-1,1-dimethyl-2-oxoethyl)-4-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-15-7 CAPLUS

CN Pyrimidine, 2-methyl-4-(2'-phenoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-16-8 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-(2'-phenoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-17-9 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-(2'-phenoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)

10/513699




RN 770724-18-0 CAPLUS

CN Pyrimidine, 4-(2'-chloro[1,1'-biphenyl]-3-yl)-2-methyl- (CA INDEX NAME)




RN 770724-22-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(1,1-dimethylethyl)-3'-(2-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 770724-23-7 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, 3'-(2-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 770724-24-8 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[2'--[(1,1-dimethylethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770724-25-9 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'--[(1,1-dimethylethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-33-9 CAPLUS

CN Pyrimidine, 4-[2'-(1,1-dimethylethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770724-34-0 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2'-(1,1-dimethylethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-35-1 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'-(1,1-dimethylethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)


<12/04/2007>

Erich Leese


10/513699




RN 770724-36-2 CAPLUS
CN Pyrimidine, 4-[2'-(cyclopropyloxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770724-37-3 CAPLUS
CN 2-Pyrimidinecarboxylic acid, 4-[2'-(cyclopropyloxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-38-4 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[2'-(cyclopropyloxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-39-5 CAPLUS
CN Pyrimidine, 2-methyl-4-[2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)


10/513699




RN 770724-40-8 CAPLUS
CN 2-Pyrimidinecarboxylic acid, 4-[2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-41-9 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-42-0 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(2'-formyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-43-1 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770724-44-2 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770724-51-1 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(2'-methyl[1,1'-biphenyl]-3-yl)- (CA INDEX
NAME)



RN 770724-54-4 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]- (CA
INDEX NAME)



RN 770724-58-8 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-(2'-fluoro[1,1'-biphenyl]-3-yl)- (CA INDEX
NAME)

10/513699




RN 770724-59-9 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(2',6'-difluoro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-60-2 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-62-4 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-(4'-acetyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-63-5 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-(3'-acetyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)

10/513699




RN 770724-64-6 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[3'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-65-7 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(4'-cyano[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-68-0 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[1,1'-biphenyl]-3-yl- (CA INDEX NAME)



RN 770724-78-2 CAPLUS


CN 2-Pyrimidineacetamide, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770724-79-3 CAPLUS

CN 2-Pyrimidineacetonitrile, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770724-83-9 CAPLUS

CN 2-Pyrimidinemethanol, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA
INDEX NAME)



RN 770724-84-0 CAPLUS


CN 2-Pyrimidinemethanol, α -methyl-4-[2'-(trifluoromethoxy)[1,1'-
biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-85-1 CAPLUS


CN Acetamide, N-[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-
pyrimidinyl]methyl]- (CA INDEX NAME)

10/513699




RN 770724-86-2 CAPLUS

CN Sulfamic acid, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinylmethyl ester (9CI) (CA INDEX NAME)




RN 770724-97-5 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'-[(4-oxo-1-piperidinyl)methyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-01-4 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-02-5 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770725-03-6 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)




RN 770725-04-7 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[6-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-05-8 CAPLUS


CN Pyrimidine, 4-[6-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770725-06-9 CAPLUS


CN Pyrimidine, 2-methyl-4-[4-(phenylmethoxy)-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770725-07-0 CAPLUS

CN [1,1'-Biphenyl]-4-ol, 3-(2-methyl-4-pyrimidinyl)-2'-(trifluoromethoxy)-
(CA INDEX NAME)




RN 770725-08-1 CAPLUS

CN Acetamide, N-[5-(2-methyl-4-pyrimidinyl)-2'-(trifluoromethoxy)[1,1'-
biphenyl]-2-yl]- (CA INDEX NAME)



RN 770725-09-2 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[6-(acetamino)-2'-(trifluoromethoxy)[1,1'-
biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



RN 770725-10-5 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[6-(acetamino)-2'-(trifluoromethoxy)[1,1'-
biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770725-11-6 CAPLUS

CN Pyrimidine, 4-[4-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)




RN 770725-12-7 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[4-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



RN 770725-13-8 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[4-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-14-9 CAPLUS


CN Pyrimidine, 4-[6-bromo-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)

10/513699




RN 770725-15-0 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-bromo-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)




RN 770725-16-1 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[6-bromo-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-17-2 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[6-bromo-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-18-3 CAPLUS


CN Pyrimidine, 2-methyl-4-[2'-(trifluoromethoxy)[1,1':2',1''-terphenyl]-4'-yl]- (9CI) (CA INDEX NAME)

10/513699




RN 770725-19-4 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2'-(trifluoromethoxy)[1,1':2',1''-terphenyl]-4'-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 770725-20-7 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'-(trifluoromethoxy)[1,1':2',1''-terphenyl]-4'-yl]- (9CI) (CA INDEX NAME)



RN 770725-21-8 CAPLUS


CN Pyrimidine, 4-[6-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770725-22-9 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[6-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)

10/513699




RN 770725-23-0 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770725-24-1 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[6-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-25-2 CAPLUS


CN Pyrimidine, 4-[4-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770725-26-3 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[4-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)

10/513699




RN 770725-27-4 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[4-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770725-28-5 CAPLUS

CN Pyrimidine, 4-[6-fluoro-2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770725-29-6 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[6-fluoro-2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



RN 770725-30-9 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[6-fluoro-2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770725-31-0 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[6-fluoro-2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770725-32-1 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[6-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-33-2 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[2'-fluoro-6-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770727-16-7 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[2',6'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699



RN 770727-17-8 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2',6'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



<12/04/2007>

Erich Leese

10/513699

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	7.37	1500.27
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.80	-4.80

FILE 'REGISTRY' ENTERED AT 15:26:12 ON 27 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1
DICTIONARY FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	6.90	1507.17
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-4.80

FILE 'REGISTRY' ENTERED AT 15:35:06 ON 27 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1
DICTIONARY FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

<12/04/2007>

Erich Leese

10/513699



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10550641claim35.str



chain nodes :
24 25 28
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
5-8 12-15 13-25 14-28 17-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
exact/norm bonds :
13-25 14-28
exact bonds :
5-8 12-15 17-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
isolated ring systems :
containing 7 : 13 :

G1:C,N

<12/04/2007>

Erich Leese

10/513699

G2:C,H

G3:C,O

G4:C,H,O,Cl,Br,F,I,At

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 24:CLASS
25:CLASS 28:CLASS

L24 STRUCTURE UPLOADED

=> d 124

L24 HAS NO ANSWERS

L24 STR



G1 C,N

G2 C,H

G3 C,O

G4 C,H,O,Cl,Br,F,I,At

Structure attributes must be viewed using STN Express query preparation.

=> s 124 ful

FULL SEARCH INITIATED 15:35:44 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 9106 TO ITERATE

100.0% PROCESSED 9106 ITERATIONS

156 ANSWERS

SEARCH TIME: 00.00.01

L25 156 SEA SSS FUL L24

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

1685.53

<12/04/2007>

Erich Leese

10/513699

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.80

FILE 'CAPLUS' ENTERED AT 15:35:48 ON 27 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 May 2008 VOL 148 ISS 22
FILE LAST UPDATED: 26 May 2008 (20080526/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 125 full
L26 1 L25

=> d ibib abs hitstr tot

10/513699

L26 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:817651 CAPLUS

DOCUMENT NUMBER: 141:332206

TITLE: Preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers

INVENTOR(S): Chakravarty, Prasun K.; Fisher, Michael H.; Parsons, William H.; Liang, Jun; Zhou, Bishan

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004084824	A2	20041007	WO 2004-US8532	20040319
WO 2004084824	A3	20050331		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004224392	A1	20041007	AU 2004-224392	20040319
CA 2519677	A1	20041007	CA 2004-2519677	20040319
EP 1608622	A2	20051228	EP 2004-757920	20040319
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
CN 1791580	A	20060621	CN 2004-80013599	20040319
JP 2006521357	T	20060921	JP 2006-507395	20040319
IN 2005DN04098	A	20070831	IN 2005-DN4098	20050912
US 20060293339	A1	20061228	US 2005-550641	20050923
PRIORITY APPLN. INFO.:			US 2003-456312P	P 20030324
			WO 2004-US8532	A 20040319

OTHER SOURCE(S): MARPAT 141:332206

GI




- AB The title biaryl substituted pyridine, pyrimidine and pyrazine compds. [I or II; H-1 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; H-2 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; R4, R5 = H, alkyl, alkoxy, aryloxy, etc.; R6-R8 = H, alkyl, cycloalkyl, alkoxy, etc.] which are sodium channel blockers useful for the treatment of pain (no data), were prepared E.g., a 2-step synthesis of III, starting from 2-bromo-6-methylpyridine and 3-bromophenylboronic acid, was given. Claimed pharmaceutical compns. comprise an effective amount of the instant compds. I, either alone, or in combination with one or more therapeutically active compds., and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compds., either alone, or in combination with one or more other therapeutically active compds.
- IT 770723-58-5P 770723-59-6P 770724-99-7P
770725-00-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers for treatment or prevention of pain)
- RN 770723-58-5 CAPLUS
- CN Pyrimidine, 2-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



10/513699


RN 770723-59-6 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770724-99-7 CAPLUS

CN Pyrimidine, 4-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770725-00-3 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



IT	770723-60-9P	770723-70-1P	770723-71-2P
	770723-72-3P	770723-73-4P	770723-74-5P
	770723-75-6P	770723-76-7P	770723-77-8P
	770723-78-9P	770723-79-0P	770723-80-3P
	770723-81-4P	770723-82-5P	770723-83-6P
	770723-84-7P	770723-85-8P	770723-86-9P
	770723-87-0P	770723-88-1P	770723-89-2P
	770723-90-5P	770723-91-6P	770723-92-7P
	770723-93-8P	770723-94-9P	770723-98-3P
	770724-00-0P	770724-01-1P	770724-06-6P
	770724-08-8P	770724-09-9P	770724-10-2P
	770724-11-3P	770724-12-4P	770724-13-5P
	770724-14-6P	770724-15-7P	770724-16-8P
	770724-17-9P	770724-18-0P	770724-19-1P
	770724-20-4P	770724-21-5P	770724-22-6P
	770724-23-7P	770724-24-8P	770724-25-9P
	770724-26-0P	770724-27-1P	770724-28-2P
	770724-29-3P	770724-30-6P	770724-31-7P
	770724-32-8P	770724-33-9P	770724-34-0P


770724-35-1P 770724-36-2P 770724-37-3P
 770724-38-4P 770724-39-5P 770724-40-8P
 770724-41-9P 770724-42-0P 770724-43-1P
 770724-44-2P 770724-45-3P 770724-46-4P
 770724-47-5P 770724-48-6P 770724-49-7P
 770724-50-0P 770724-51-1P 770724-52-2P
 770724-53-3P 770724-54-4P 770724-55-5P
 770724-56-6P 770724-57-7P 770724-58-8P
 770724-59-9P 770724-60-2P 770724-61-3P
 770724-62-4P 770724-63-5P 770724-64-6P
 770724-65-7P 770724-66-8P 770724-67-9P
 770724-68-0P 770724-69-1P 770724-70-4P
 770724-71-5P 770724-72-6P 770724-73-7P
 770724-78-2P 770724-79-3P 770724-83-9P
 770724-84-0P 770724-85-1P 770724-86-2P
 770724-90-8P 770724-91-9P 770724-92-0P
 770724-93-1P 770724-94-2P 770724-95-3P
 770724-96-4P 770724-97-5P 770724-98-6P
 770725-01-4P 770725-02-5P 770725-03-6P
 770725-04-7P 770725-05-8P 770725-06-9P
 770725-07-0P 770725-08-1P 770725-09-2P
 770725-10-5P 770725-11-6P 770725-12-7P
 770725-13-8P 770725-14-9P 770725-15-0P
 770725-16-1P 770725-17-2P 770725-18-3P
 770725-19-4P 770725-20-7P 770725-21-8P
 770725-22-9P 770725-23-0P 770725-24-1P
 770725-25-2P 770725-26-3P 770725-27-4P
 770725-28-5P 770725-29-6P 770725-30-9P
 770725-31-0P 770725-32-1P 770725-33-2P
 770727-13-4P 770727-14-5P 770727-15-6P
 770727-16-7P 770727-17-8P 770727-18-9P
 770727-19-0P 770727-20-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of biaryl substituted 6-membered heterocycles as sodium channel
 blockers for treatment or prevention of pain)

RN 770723-60-9 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-
 (CA INDEX NAME)



RN 770723-70-1 CAPLUS


CN 2-Pyrimidinecarboxamide, N-methoxy-N-methyl-4-[2'-(trifluoromethoxy)[1,1'-
 biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770723-71-2 CAPLUS

CN Methanone, 4-morpholinyl[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]- (CA INDEX NAME)




RN 770723-72-3 CAPLUS

CN Ethanone, 1-[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 770723-73-4 CAPLUS


CN Alanine, 2-methyl-N-[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]carbonyl]-, methyl ester (CA INDEX NAME)



RN 770723-74-5 CAPLUS


CN 2-Pyrimidinecarboxamide, N-(2-cyanoethyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770723-75-6 CAPLUS

CN Alanine, 2-methyl-N-[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]carbonyl]- (CA INDEX NAME)




RN 770723-76-7 CAPLUS

CN 2-Pyrimidinecarboxamide, N-(2-amino-1,1-dimethyl-2-oxoethyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-77-8 CAPLUS


CN Methanone, 1-piperazinyl[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 770723-78-9 CAPLUS


CN 2-Pyrimidinecarboxamide, N-2H-tetrazol-5-yl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770723-79-0 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)




RN 770723-80-3 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]carbonyl]amino]- (CA INDEX NAME)



RN 770723-81-4 CAPLUS


CN 2-Pyrimidinecarboxamide, N-[1-(aminocarbonyl)cyclopropyl]-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-82-5 CAPLUS


CN 2-Pyrimidinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770723-83-6 CAPLUS

CN 2-Pyrimidinecarboxamide, N-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-84-7 CAPLUS

CN 2-Pyrimidinecarboxamide, N,N-dimethyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-85-8 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)




RN 770723-86-9 CAPLUS

CN 2-Pyrimidinecarboxamide, N-[(1S)-2-amino-1-methyl-2-oxoethyl]-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 770723-87-0 CAPLUS

CN 2-Pyrimidinecarboxamide, N-[2-(1-piperidiny)ethyl]-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-88-1 CAPLUS

CN 2-Pyrimidinecarboxamide, N-(1,1-dimethylethyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-89-2 CAPLUS

CN 2-Pyrimidinecarboxamide, N-[(1R)-2-amino-1-methyl-2-oxoethyl]-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 770723-90-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]carbonyl]- (CA INDEX NAME)



RN 770723-91-6 CAPLUS


CN Pyrimidine, 2,5-dimethyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-92-7 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 5-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770723-93-8 CAPLUS

CN 2-Pyrimidinecarboxamide, 5-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-94-9 CAPLUS

CN 2-Pyrimidinecarboxamide, N-(2-amino-2-oxoethyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-98-3 CAPLUS

CN Pyrimidine, 2-methyl-4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-00-0 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-


10/513699

(CA INDEX NAME)




RN 770724-01-1 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770724-06-6 CAPLUS

CN 2-Pyrimidinecarbonitrile, 4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)



RN 770724-08-8 CAPLUS

CN Pyrimidine, 4-[5'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2-
methyl- (CA INDEX NAME)




RN 770724-09-9 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[5'-fluoro-2'-(trifluoromethyl)[1,1'-


10/513699

biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-10-2 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[5'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-11-3 CAPLUS

CN Pyrimidine, 4-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770724-12-4 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




<12/04/2007>

Erich Leese

10/513699


RN 770724-13-5 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-14-6 CAPLUS

CN 2-Pyrimidinecarboxamide, N-(2-amino-1,1-dimethyl-2-oxoethyl)-4-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-15-7 CAPLUS

CN Pyrimidine, 2-methyl-4-(2'-phenoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-16-8 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-(2'-phenoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-17-9 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(2'-phenoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)

<12/04/2007>


Erich Leese

10/513699




RN 770724-18-0 CAPLUS

CN Pyrimidine, 4-(2'-chloro[1,1'-biphenyl]-3-yl)-2-methyl- (CA INDEX NAME)




RN 770724-19-1 CAPLUS

CN Pyrimidine, 4-(3'-chloro[1,1'-biphenyl]-3-yl)-2-methyl- (CA INDEX NAME)



RN 770724-20-4 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, N-(1,1-dimethylethyl)-3'-(2-methyl-4-pyrimidinyl)- (CA INDEX NAME)




RN 770724-21-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 3'-(2-methyl-4-pyrimidinyl)- (CA INDEX NAME)


10/513699




RN 770724-22-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(1,1-dimethylethyl)-3'-(2-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 770724-23-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 3'-(2-methyl-4-pyrimidinyl)- (CA INDEX NAME)




RN 770724-24-8 CAPLUS
CN 2-Pyrimidinecarboxylic acid, 4-[2'-[[(1,1-dimethylethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-25-9 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[2'-[[(1,1-dimethylethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)


10/513699




RN 770724-26-0 CAPLUS
CN 2-Pyrimidinecarboxylic acid, 4-(2',3'-dichloro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-27-1 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(2',3'-dichloro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-28-2 CAPLUS
CN 2-Pyrimidinecarboxylic acid, 4-(2',3'-dichloro[1,1'-biphenyl]-3-yl)-, methyl ester (CA INDEX NAME)




RN 770724-29-3 CAPLUS
CN 2-Pyrimidinecarboxylic acid, 4-[2'-[[(1,1-dimethylethyl) amino]sulfonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770724-30-6 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770724-31-7 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'-[(1,1-dimethylethyl)amino]sulfonyl][1,1'-
biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-32-8 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[2'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]- (CA
INDEX NAME)




RN 770724-33-9 CAPLUS

CN Pyrimidine, 4-[2'-(1,1-dimethylethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA
INDEX NAME)


10/513699




RN 770724-34-0 CAPLUS
CN 2-Pyrimidinecarboxylic acid, 4-[2'-(1,1-dimethylethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-35-1 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[2'-(1,1-dimethylethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-36-2 CAPLUS
CN Pyrimidine, 4-[2'-(cyclopropyloxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)




RN 770724-37-3 CAPLUS
CN 2-Pyrimidinecarboxylic acid, 4-[2'-(cyclopropyloxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770724-38-4 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'-(cyclopropyloxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-39-5 CAPLUS

CN Pyrimidine, 2-methyl-4-[2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-40-8 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-41-9 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770724-42-0 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(2'-formyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-43-1 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-44-2 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-45-3 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(3'-fluoro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)


10/513699




RN 770724-46-4 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(4'-chloro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-47-5 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(4'-fluoro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-48-6 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-49-7 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(2',3'-dimethoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)

10/513699




RN 770724-50-0 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(5'-chloro-2'-methoxy[1,1'-biphenyl]-3-yl)-
(CA INDEX NAME)




RN 770724-51-1 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(2'-methyl[1,1'-biphenyl]-3-yl)- (CA INDEX
NAME)



RN 770724-52-2 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-(3'-fluoro-2'-methyl[1,1'-biphenyl]-3-yl)- (CA
INDEX NAME)



RN 770724-53-3 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[2'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)

10/513699




RN 770724-54-4 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-55-5 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(3'-chloro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-56-6 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-(3'-ethoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-57-7 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(4'-ethoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)


10/513699




RN 770724-58-8 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(2'-fluoro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-59-9 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(2',6'-dimethyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-60-2 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-61-3 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[4'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)


10/513699




RN 770724-62-4 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(4'-acetyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-63-5 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(3'-acetyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-64-6 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[3'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-65-7 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(4'-cyano[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)

10/513699




RN 770724-66-8 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[3'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770724-67-9 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(2',4'-difluoro[1,1'-biphenyl]-3-yl)- (CA
INDEX NAME)



RN 770724-68-0 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[1,1'-biphenyl]-3-yl- (CA INDEX NAME)



RN 770724-69-1 CAPLUS


CN Methanesulfonamide, N-methyl-N-[3'-(2-methyl-4-pyrimidinyl)-2-
(trifluoromethoxy)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)

10/513699




RN 770724-70-4 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[4'-(2-methyl(ethylsulfonyl)amino)-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-71-5 CAPLUS


CN Propanamide, 2,2-dimethyl-N-[3'-(2-methyl-4-pyrimidinyl)-2'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 770724-72-6 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[4'-(2,2-dimethyl-1-oxopropyl)amino]-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770724-73-7 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[4'-(2,2-dimethyl-1-oxopropyl)amino]-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl- (CA INDEX NAME)




RN 770724-78-2 CAPLUS

CN 2-Pyrimidineacetamide, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-79-3 CAPLUS


CN 2-Pyrimidineacetonitrile, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-83-9 CAPLUS


CN 2-Pyrimidinemethanol, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770724-84-0 CAPLUS

CN 2-Pyrimidinemethanol, α-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-85-1 CAPLUS

CN Acetamide, N-[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]methyl]- (CA INDEX NAME)



RN 770724-86-2 CAPLUS


CN Sulfamic acid, [4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]methyl ester (9CI) (CA INDEX NAME)



RN 770724-90-8 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[3-(8-quinolinyl)phenyl]- (CA INDEX NAME)

10/513699




RN 770724-91-9 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(3-benzo[b]thien-7-ylphenyl)- (CA INDEX NAME)



RN 770724-92-0 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[3-(2-methyl-5-quinolinyl)phenyl]- (CA INDEX NAME)



RN 770724-93-1 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[3-(6-quinolinyl)phenyl]- (CA INDEX NAME)

10/513699




RN 770724-94-2 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-95-3 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[3-(1-naphthalenyl)phenyl]- (CA INDEX NAME)



RN 770724-96-4 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[3-(5-quinolinyl)phenyl]- (CA INDEX NAME)



10/513699


RN 770724-97-5 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'-[(4-oxo-1-piperidiny)methyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-98-6 CAPLUS

CN 1H-Indole-1-carboxylic acid, 5-[3-[2-(aminocarbonyl)-4-pyrimidinyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 770725-01-4 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-02-5 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




<12/04/2007>

Erich Leese

10/513699


RN 770725-03-6 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)




RN 770725-04-7 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[6-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770725-05-8 CAPLUS

CN Pyrimidine, 4-[6-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770725-06-9 CAPLUS


CN Pyrimidine, 2-methyl-4-[4-(phenylmethoxy)-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-07-0 CAPLUS


CN [1,1'-Biphenyl]-4-ol, 3-(2-methyl-4-pyrimidinyl)-2'-(trifluoromethoxy)- (CA INDEX NAME)

10/513699




RN 770725-08-1 CAPLUS

CN Acetamide, N-[5-(2-methyl-4-pyrimidinyl)-2'-(trifluoromethoxy)[1,1'-biphenyl]-2-yl]- (CA INDEX NAME)




RN 770725-09-2 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-(acetylamino)-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



RN 770725-10-5 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[6-(acetylamino)-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-11-6 CAPLUS


CN Pyrimidine, 4-[4-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)

10/513699




RN 770725-12-7 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[4-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)




RN 770725-13-8 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[4-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-14-9 CAPLUS


CN Pyrimidine, 4-[6-bromo-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770725-15-0 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[6-bromo-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)

10/513699




RN 770725-16-1 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[6-bromo-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770725-17-2 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-bromo-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-18-3 CAPLUS


CN Pyrimidine, 2-methyl-4-[2'-(trifluoromethoxy)[1,1':2',1''-terphenyl]-4'-yl]- (9CI) (CA INDEX NAME)



RN 770725-19-4 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[2'-(trifluoromethoxy)[1,1':2',1''-terphenyl]-4'-yl]-, methyl ester (9CI) (CA INDEX NAME)

10/513699




RN 770725-20-7 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'-(trifluoromethoxy)[1,1':2',1''-terphenyl]-4'-yl]- (9CI) (CA INDEX NAME)




RN 770725-21-8 CAPLUS

CN Pyrimidine, 4-[6-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770725-22-9 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[6-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



RN 770725-23-0 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[6-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770725-24-1 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[6-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770725-25-2 CAPLUS

CN Pyrimidine, 4-[4-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770725-26-3 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[4-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



RN 770725-27-4 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[4-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770725-28-5 CAPLUS

CN Pyrimidine, 4-[6-fluoro-2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)




RN 770725-29-6 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-fluoro-2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



RN 770725-30-9 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[6-fluoro-2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-31-0 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[6-fluoro-2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770725-32-1 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[6-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770725-33-2 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'-fluoro-6-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770727-13-4 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[4'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770727-14-5 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[4'-chloro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770727-15-6 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(2',6'-dichloro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770727-16-7 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2',6'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770727-17-8 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[2',6'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770727-18-9 CAPLUS


CN Pyrimidine, 4-[4'-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2,5-dimethyl- (CA INDEX NAME)

10/513699




RN 770727-19-0 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[4'-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl-, methyl ester (CA INDEX NAME)



RN 770727-20-3 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[4'-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



10/513699

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

8.81

1694.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.80

-5.60

FILE 'REGISTRY' ENTERED AT 15:40:01 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

DICTIONARY FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10550641claim34.str



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

5-8 12-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18

14-15 15-16 16-17 17-18

exact bonds :

5-8 12-15

normalized bonds :

<12/04/2007>

Erich Leese

10/513699

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 7 : 13 :

G1:C,N

G2:C,H

G3:C,O

G4:C,H,O,Cl,Br,F,I,At

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L27 STRUCTURE UPLOADED

=> d 127

L27 HAS NO ANSWERS

L27 STR



G1 C,N

G2 C,H

G3 C,O

G4 C,H,O,Cl,Br,F,I,At

Structure attributes must be viewed using STN Express query preparation.

=> s 127 full

FULL SEARCH INITIATED 15:40:36 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 14858 TO ITERATE

100.0% PROCESSED 14858 ITERATIONS

346 ANSWERS

SEARCH TIME: 00.00.01

<12/04/2007>

Erich Leese

10/513699

L28 346 SEA SSS FUL L27

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	178.36	1872.70
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-5.60

FILE 'CAPLUS' ENTERED AT 15:40:40 ON 27 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 May 2008 VOL 148 ISS 22
FILE LAST UPDATED: 26 May 2008 (20080526/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l28 full

L29 29 L28

=> d ibib abs hitstr tot


10/513699

L29 ANSWER 1 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:156813 CAPLUS
DOCUMENT NUMBER: 148:225226
TITLE: Organic electroluminescent device
INVENTOR(S): Iwakuma, Toshihiro; Arakane, Takashi; Arai, Hiromasa;
Nagashima, Hideaki
PATENT ASSIGNEE(S): Idemitsu Kosan Co., Ltd., Japan
SOURCE: PCT Int. Appl., 71pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008015949	A1	20080207	WO 2007-JP64631	20070726
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: JP 2006-213761 A 20060804
AB The invention relates to an organic electroluminescent device comprising a cathode, an anode, and an organic layer, which is formed between the cathode and the anode and includes at least a light-emitting layer and an electron transport layer. An electron transport material constituting the electron transport layer and having the slowest electron mobility has an electron mobility of $2.0 + 10^{-5}$ cm²/Vs or more at an elec. field intensity of 0.4 MV/cm to 0.5 MV/cm. When the ratio of the electron mobility to the hole mobility of a host material constituting the light-emitting layer is denoted by ΔEM and the ratio of the electron mobility to the hole mobility of the electron transport material constituting the electron transport layer and having the slowest electron mobility is denoted by ΔET , the organic electroluminescence device satisfies the following relationships: $\Delta ET > 1$, $0.3 \leq \Delta EM \leq 10$, and $\Delta ET > \Delta EM$.
IT 864377-29-7
RL: TEM (Technical or engineered material use); USES (Uses)
(organic electroluminescent device)
RN 864377-29-7 CAPLUS
CN 9H-Carbazole, 9-[3'-(2,6-diphenyl-4-pyrimidinyl)[1,1'-biphenyl]-4-yl]-
(CA INDEX NAME)

10/513699



REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1420328 CAPLUS

DOCUMENT NUMBER: 148:67473

TITLE: Material for organic electroluminescence element, and organic electroluminescence element using the material

INVENTOR(S): Iwakuma, Toshihiro; Matsuura, Masahide; Nakano, Yuki; Ikeda, Hidetsugu

PATENT ASSIGNEE(S): Idemitsu Kosan Co., Ltd., Japan

SOURCE: PCT Int. Appl., 65pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007142083	A1	20071213	WO 2007-JP60921	20070529
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: JP 2006-154305 A 20060602

AB Provided are an organic electroluminescence element composed of a compound including a hetero atom having a specific structure, and an organic electroluminescence element wherein an organic thin film layer, which is composed of one or a plurality of layers including at least a light emitting layer, is sandwiched between an anode and a cathode. The organic electroluminescence element, which has high emission efficiency, no pixel defect, excellent heat resistance and a long life, is provided by permitting the organic thin film layer to include the organic EL element material. The organic electroluminescence element material for providing such organic electroluminescence element is also provided.


IT 864377-29-7

RL: TEM (Technical or engineered material use); USES (Uses)
(material for organic electroluminescence element, and organic electroluminescence element using the material)

RN 864377-29-7 CAPLUS

CN 9H-Carbazole, 9-[3'-(2,6-diphenyl-4-pyrimidinyl)[1,1'-biphenyl]-4-yl]-
(CA INDEX NAME)

10/513699



REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 3 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:971415 CAPLUS

DOCUMENT NUMBER: 147:311076

TITLE: Organic electroluminescent device

INVENTOR(S): Iwakuma, Toshihiro; Matsuura, Masahide; Nagashima, Hideaki; Ikeda, Shuji; Nakamura, Hiroaki; Kusumoto, Tadashi

PATENT ASSIGNEE(S): Idemitsu Kosan Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 20pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007220721	A	20070830	JP 2006-36479	20060214
PRIORITY APPLN. INFO.:			JP 2006-36479	20060214

AB The invention relates to an organic electroluminescent device, especially relates


to a phosphorescent organic electroluminescent device, comprising a 1st layer, a 2nd layer, an active layer containing a ortho-metalated complex doped in a host material, and a cathode, stacked in that order on an anode, wherein the relationships represented by $TD + 10 \text{ eV} \leq Th1$, $TD + 0.10 \text{ eV} \leq Th2$, and $TD + 0.10 \text{ eV} \leq TH$ are satisfied, wherein the TD, Th1, Th2 and TH are the lowest excited triplet state energy of ortho-metalated complex, the 1st layer material, the 2d layer material and the active layer host, resp., in order to realize the high quantum efficiency device.

IT 864377-29-7

RL: TEM (Technical or engineered material use); USES (Uses)
(organic electroluminescent device)

RN 864377-29-7 CAPLUS

CN 9H-Carbazole, 9-[3'-(2,6-diphenyl-4-pyrimidinyl)[1,1'-biphenyl]-4-yl]-
(CA INDEX NAME)



10/513699


<12/04/2007>

Erich Leese

10/513699

L29 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:640321 CAPLUS
DOCUMENT NUMBER: 147:46155
TITLE: Drugs containing aminocyanopyrimidine derivatives
having adenosine A2A receptor agonistic effects
INVENTOR(S): Kato, Masaya; Sato, Norisuke; Okada, Minoru; Uno,
Tetsuyuki; Ito, Nobuaki; Takeji, Yasuhiro; Shinohara,
Hisashi; Fuwa, Masahiro
PATENT ASSIGNEE(S): Ohtsuka Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 292pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
JP 2007145828	A	20070614	JP 2006-293353	20061027
PRIORITY APPLN. INFO.:			JP 2005-315444	A 20051028
OTHER SOURCE(S):	MARPAT	147:46155		
GI				




AB The invention provide drugs having adenosine A2A receptor agonistic effects, suitable for use in treatment of eye disease, e.g. glaucoma, wherein the drugs contain compds. represented by a formula I (R¹ = (un)substituted aryl, heterocyclic; R² = C3-6 alkyl, lower alkenyl, etc.; R³ = H, lower alkyl, acyl) or their salts as active components. For example, N-[4-[6-amino-5-cyano-2-(6-methylpyridin-2-ylmethylsulfanyl)pyrimidin-4-yl]phenyl]acetamide was prepared, and examined for its effect on adenosine A2A receptor in vitro, and intraocular pressure in rabbits.

IT 939787-27-6P 939787-35-6P 939787-49-2P
939787-51-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drugs containing aminocyanopyrimidine derivs. having adenosine A2A receptor agonistic effects)


RN 939787-27-6 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-[1,1'-biphenyl]-3-yl-2-[(3-pyridinylmethyl)thio]- (CA INDEX NAME)

10/513699




RN 939787-35-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-amino-6-[1,1'-biphenyl]-3-yl-2-[[2-methyl-4-thiazolyl)methyl]thio]- (CA INDEX NAME)



RN 939787-49-2 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-amino-6-[1,1'-biphenyl]-3-yl-2-[[2-cyanophenyl)methyl]thio]- (CA INDEX NAME)



RN 939787-51-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-amino-6-[1,1'-biphenyl]-3-yl-2-[[3-nitrophenyl)methyl]thio]- (CA INDEX NAME)

10/513699



<12/04/2007>

Erich Leese

L29 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:283477 CAPLUS

DOCUMENT NUMBER: 146:307085

TITLE: Blue-light emitting organic electroluminescence element

INVENTOR(S): Matsuura, Masahide; Iwakuma, Toshihiro

PATENT ASSIGNEE(S): Idemitsu Kosan Co., Ltd., Japan

SOURCE: PCT Int. Appl., 39pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007029426	A1	20070315	WO 2006-JP314795	20060726
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1923930	A1	20080521	EP 2006-781707	20060726
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
US 20070069638	A1	20070329	US 2006-498071	20060803
KR 2008041682	A	20080513	KR 2008-705347	20080304
PRIORITY APPLN. INFO.:			JP 2005-256448	A 20050905
			WO 2006-JP314795	W 20060726
AB	A blue-light emitting organic electroluminescence element is provided with at least a light emitting layer between an anode and a cathode. The light emitting layer contains a host material and a plurality of kinds of dopants. At least one of the dopants has UV emitting characteristics.			
IT	862423-40-3			
	RL: TEM (Technical or engineered material use); USES (Uses) (electron transport layers; blue-light emitting organic electroluminescent devices)			
RN	862423-40-3 CAPLUS			
CN	9H-Carbazole, 9,9'-(5'-(2,6-diphenyl-4-pyrimidinyl)[1,1':3',1''-terphenyl]-4,4''-diyl]bis- (CA INDEX NAME)			

10/513699



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

<12/04/2007>

Erich Leese

L29 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:257447 CAPLUS

DOCUMENT NUMBER: 146:261785

TITLE: Organic electroluminescence device

INVENTOR(S): Iwakuma, Toshihiro; Matsuura, Masahide; Nagashima, Hideaki; Ikeda, Hidetsugu; Nakamura, Hiroaki; Kusumoto, Tadashi

PATENT ASSIGNEE(S): Idemitsu Kosan Co., Ltd., Japan

SOURCE: U.S. Pat. Appl. Publ., 14pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070052346	A1	20070308	US 2006-480465	20060705
WO 2007029402	A1	20070315	WO 2006-JP312891	20060628
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: JP 2005-260272 A 20050908

AB An organic electroluminescent device is described comprising an anode, a cathode, and at least a first layer, a second layer, and a third layer provided between the anode and the cathode; at least one of the first to third layers including a phosphorescent compound, at least one of the first to third layers being an emitting layer, and compds. resp. forming the first to third layers and having the largest ionization potentials of the resp. layers having an ionization potential of 5.7 eV or more and differing in the ionization potential in an amount of less than 1.0 eV.


IT 862423-40-3

RL: TEM (Technical or engineered material use); USES (Uses)
(electron transporting layer; organic electroluminescence device having layers of phosphorescent compound)

RN 862423-40-3 CAPLUS

CN 9H-Carbazole, 9,9'-(5'-(2,6-diphenyl-4-pyrimidinyl)[1,1':3',1''-terphenyl]-4,4''-diyl]bis- (CA INDEX NAME)

10/513699



<12/04/2007>


Erich Leese

L29 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1228974 CAPLUS
 DOCUMENT NUMBER: 145:505475
 TITLE: Preparation of azinamines as modulators of heat shock protein 90 (Hsp90).
 INVENTOR(S): Chessari, Gianni; Congreve, Miles Stuart; Callaghan, Owen; Cowan, Suzanna Ruth; Murray, Christopher William; Woolford, Alison Jo-Anne; O'Brien, Michael Alistair; Woodhead, Andrew James
 PATENT ASSIGNEE(S): Astex Therapeutics Limited, UK
 SOURCE: PCT Int. Appl., 159pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006123165	A2	20061123	WO 2006-GB1851	20060519
WO 2006123165	A3	20071011		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: GB 2005-10252 A 20050519
 US 2005-682687P P 20050519

OTHER SOURCE(S): MARPAT 145:505475
 GI



AB Title compds. [I; A = N, CR₃; R₁ = (substituted) mono- or bicyclic (hetero)cyclic ring of 5-10 ring members of which ≤2 ring members may be N, O, S and the remainder are C atoms; R₂ = H, halo, CF₃, cyano, amino, (substituted) alicyclic hydrocarbonyl, etc.; R₃ = R₂, (substituted) monocyclic (hetero)cyclyl], were prepared Thus, 4-(2-chloro-6-methoxyphenyl)-6-methylpyrimidin-2-ylamine (prepared from 2-amino-4-chloro-6-methylpyrimidine and 2-chloro-6-methoxyphenylboronic acid) showed a K_d value of <1 μM in isothermal titration calorimetry expts. using Hsp90α.

10/513699


IT 915070-13-2P 915070-14-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azinamines as modulators of heat shock protein 90)


RN 915070-13-2 CAPLUS

CN 2-Pyrimidinamine, 4-chloro-6-(2,4-dimethoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 915070-14-3 CAPLUS

CN 2-Pyrimidinamine, 4-(3'-bromo-2,2',4,6'-tetramethoxy[1,1'-biphenyl]-3-yl)-6-chloro- (CA INDEX NAME)



10/513699

L29 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:632732 CAPLUS

DOCUMENT NUMBER: 145:103546

TITLE: Preparation of biscarbazole derivatives as
charge-transporting materials, and organic
electroluminescent elements

INVENTOR(S): Yabe, Masayoshi; Sato, Hideki

PATENT ASSIGNEE(S): Pioneer Corporation, Japan; Mitsubishi Chemical
Corporation

SOURCE: PCT Int. Appl., 137 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2006067976	A1	20060629	WO 2005-JP22635	20051209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
JP 2006199679	A	20060803	JP 2005-355790	20051209
EP 1829871	A1	20070905	EP 2005-814748	20051209
R: DE				
CN 101087776	A	20071212	CN 2005-80044718	20051209
KR 2007090952	A	20070906	KR 2007-714364	20070622
PRIORITY APPLN. INFO.:			JP 2004-373981	A 20041224
			WO 2005-JP22635	W 20051209
OTHER SOURCE(S):			CASREACT 145:103546; MARPAT 145:103546	
GI				



III

AB Organic compds. represented by the following formula [I; Cz1, Cz2 = carbazolyl; Z = a direct bond or any connecting group which enables the nitrogen atom of the carbazole ring in Cz1 to be conjugated with the nitrogen atom of the carbazole ring in Cz2; Q = a direct bond connected to G in the following formula Q1; ring B1 = a 6-membered aromatic heterocycle having n nitrogen atom(s) as a heteroatom, provided that n is an integer of 1-3; G is connected to Q, it is a direct bond or any connecting group which each is connected to Q; G is bonded to any of the carbon atoms located in the ortho and para positions to a nitrogen atom of the ring B1; when G is not connected to Q, it is an aromatic hydrocarbon group; m = an integer of 3-5] are prepared. These compds. combines excellent hole-transporting properties with excellent electron-transporting properties and has excellent long-term resistance to elec. oxidation/reduction and a high triplet excitation level. A charge-transporting material and an organic electroluminescent element which comprise or employ the organic compound I are also disclosed. Thus, aldol condensation of 2,5-difluorobenzaldehyde with acetophenone in a mixture of concentrated H₂SO₄

and

THF at 35° for 7 h gave 1-phenyl-3-(2,5-difluorophenyl)-2-propen-1-one which underwent cyclocondensation with 1-phenacylpyridinium bromide and ammonium acetate in a mixture of AcOH and DMF under refluxing for 6 h to give 4-(2,5-difluorophenyl)-2,6-diphenylpyridine (II). Carbazole was treated with NaH in DMF at 80° for 60 min and condensed with II under refluxing for 3 h to give 4-[2,5-bis(carbazol-9-yl)phenyl]-2,6-diphenylpyridine (III). An electroluminescent device with a luminescent layer comprising III as a main component (host material) showed excellent life property (working life of 1.00 at 2.500 cd/m²).

IT 895146-85-7P 895146-87-9P 895146-89-1P
895147-12-3P 895147-14-5P 895147-18-9P
RL: DEV (Device component use); SPN (Synthetic preparation); TEM


10/513699

(Technical or engineered material use); PREP (Preparation); USES (Uses)
(preparation of biscarbazole derivs. as charge-transporting materials, and
organic electroluminescent elements)


RN 895146-85-7 CAPLUS

CN 9H-Carbazole, 9,9',9'',9'''-[(2-phenyl-4,6-pyrimidinediyl)bis([1,1':3',1''
:3'',1'''-quaterphenyl]-3'',2,5-triyl)]tetrakis- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B





RN 895146-87-9 CAPLUS

CN 9H-Carbazole, 9,9'-[3'''-[4-[3'''-(4,6-diphenyl-2-pyridinyl)[1,1':3',1''-
terphenyl]-3-yl]-6-phenyl-2-pyrimidinyl][1,1':3',1''':3'',1'''-
quaterphenyl]-2,5-diyl]bis- (9CI) (CA INDEX NAME)




RN 895146-89-1 CAPLUS
 CN 9H-Carbazole, 9,9',9'',9''',9'''',9'''''-[2,4,6-pyrimidinetriyltris([1,1'-biphenyl]-3',2,5-triyl)]hexakis- (9CI) (CA INDEX NAME)







RN 895147-12-3 CAPLUS

CN 9H-Carbazole, 9,9',9'',9'''-[(2-phenyl-4,6-pyrimidinediyl)bis([1,1'-biphenyl]-3',2,5-triyl)]tetrakis- (9CI) (CA INDEX NAME)




RN 895147-14-5 CAPLUS

CN 9H-Carbazole, 9-[2,5,6-tri-9H-carbazol-9-yl-3'-(2,6-diphenyl-4-pyrimidinyl)][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 895147-18-9 CAPLUS

CN 9H-Carbazole, 9,9',9'',9'''-[(2-phenyl-4,6-pyrimidinediyl)bis([1,1':3',1''-terphenyl]-3'',2,5-triyl)]tetrakis- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

16

THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 9 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1004849 CAPLUS

DOCUMENT NUMBER: 143:295331

TITLE: Organic electroluminescent material used for organic electroluminescent device

INVENTOR(S): Ikeda, Kiyoshi; Tomita, Seiji; Arakane, Takashi; Ito, Mitsunori

PATENT ASSIGNEE(S): Idemitsu Kosan Co., Ltd., Japan

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085387	A1	20050915	WO 2005-JP3783	20050304
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1724323	A1	20061122	EP 2005-720055	20050304
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1934213	A	20070321	CN 2005-80007533	20050304
IN 2006CN03250	A	20070706	IN 2006-CN3250	20060907
KR 2007030759	A	20070316	KR 2006-718427	20060908
US 20070190355	A1	20070816	US 2007-591908	20070118
PRIORITY APPLN. INFO.:			JP 2004-64004	A 20040308
			WO 2005-JP3783	W 20050304

OTHER SOURCE(S): MARPAT 143:295331

AB A material for organic electroluminescent (EL) device, comprising a compound of specified structure having a nitrogenous ring. Further, there is provided an organic EL device comprising a neg. electrode and a pos. electrode and, interposed there-between, one or two or more organic thin-film layers including at least a light-emitting layer, wherein at least one of the organic thin-film layers contains the above material for organic EL device.

The

above device containing the material is capable of realizing high luminous efficiency and thermostability and prolonged service life.

IT 650606-89-6P 862423-42-5P 864377-27-5P

864377-29-7P 864377-30-0P 864377-39-9P

864377-43-5P

RL: DEV (Device component use); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)


(organic electroluminescent material used for organic electroluminescent device)

RN 650606-89-6 CAPLUS

CN Pyrimidine, 2,4,6-tris([1,1':3',1''-terphenyl]-5'-yl)- (9CI) (CA INDEX


10/513699

NAME)




RN 862423-42-5 CAPLUS

CN 9H-Carbazole, 9-[3'-(2,6-diphenyl-4-pyrimidinyl)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)



RN 864377-27-5 CAPLUS

CN 9H-Carbazole, 9-[5'-(2,6-diphenyl-4-pyrimidinyl)[1,1':3',1''-terphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 864377-29-7 CAPLUS

<12/04/2007>

Erich Leese


10/513699

CN 9H-Carbazole, 9-[3'-(2,6-diphenyl-4-pyrimidinyl)[1,1'-biphenyl]-4-yl]-
(CA INDEX NAME)



RN 864377-30-0 CAPLUS


CN 9H-Carbazole, 9-[3'''-(2,6-diphenyl-4-pyrimidinyl)[1,1':4',1'''-terphenyl]-4-
yl]- (9CI) (CA INDEX NAME)




RN 864377-39-9 CAPLUS

CN Pyrimidine, 4,4'-[1,1'-biphenyl]-3,5-diylbis[2,6-diphenyl- (9CI) (CA
INDEX NAME)


10/513699



RN 864377-43-5 CAPLUS
CN 9H-Carbazole, 9-[3',5'-bis(2,6-diphenyl-4-pyrimidinyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



IT 864377-38-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(organic electroluminescent material used for organic electroluminescent device)
RN 864377-38-8 CAPLUS
CN 2-Propen-1-one, 3-[5-(2,6-diphenyl-4-pyrimidinyl)[1,1'-biphenyl]-3-yl]-1-phenyl- (CA INDEX NAME)



IT 864377-26-4P 864377-37-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

<12/04/2007>

Erich Leese


10/513699

(Reactant or reagent)

(organic electroluminescent material used for organic electroluminescent device)


RN 864377-26-4 CAPLUS

CN Pyrimidine, 4-(5-bromo[1,1'-biphenyl]-3-yl)-2,6-diphenyl- (CA INDEX NAME)



RN 864377-37-7 CAPLUS

CN [1,1'-Biphenyl]-3-carboxaldehyde, 5-(2,6-diphenyl-4-pyrimidinyl)- (CA INDEX NAME)




REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:1004351 CAPLUS
 DOCUMENT NUMBER: 143:306328
 TITLE: Preparation of 4-pyrimidinamines as neuroprotectants.
 INVENTOR(S): Benjamin, Elfrida R.; Brown, Frank K.; Zivin, Robert
 Allan; McMillan, Michael Kurt; Zhong, Zhong; Reitz,
 Allen B.; Ross, Tina Morgan
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S.
 Ser. No. 922,874, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 20050203092	A1	20050915	US 2004-987562	20041112
US 20030008883	A1	20030109	US 2001-922874	20010806
US 20030212079	A1	20031113	US 2003-396158	20030325
US 20040006094	A1	20040108	US 2003-395971	20030325
PRIORITY APPLN. INFO.:			US 2000-223791P	P 20000808
			US 2001-922874	B2 20010806
OTHER SOURCE(S):	MARPAT 143:306328			
GI				




AB This invention provides novel neuroprotective 4-pyrimidineamine derivs. (I, variables defined below) and neuroprotective pharmaceutical compns. comprising 4-pyrimidinamines. This invention also provides methods of using these compns. to prevent ischemic cell death, particularly neuronal cell death, and reduce the likelihood of neuronal cell death in a subject due to a traumatic event. Thus, a mixture of N-(2-aminoethyl)-N'-(6-biphenyl-3-ylpyrimidin-4-yl)-N-ethylbenzene-1,4-diamine (preparation given), N-benzoylalanine, diisopropylethylamine, HBTU, and DMF was stirred overnight at room temperature to give N-[1-[[2-[4-(6-biphenyl-3-ylpyrimidin-4-ylamino)phenyl]ethylamino]ethylcarbonyl]ethyl]benzamide. Tested compds. in a differentiated P19 cell assay using 3 mM glutamate showed neuroprotectant activity with IC50 = 0.07 μ M to >1 μ M. For I the variables are: R20 = disubstituted amino; R21 = H, alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl and aralkylcarbonyl, wherein the aryl portion is optionally substituted; p = 0-3; q = 0-3; R22 and R23 = halogen, alkyl, alkoxy, amino, alkylamino, dialkylamino, nitro, cyano, carboxy, alkoxycarbonyl, aryloxy, aryloxy, aminocarbonyl, alkylaminocarbonyl and dialkylaminocarbonyl.

10/513699

IT 397850-40-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 4-pyrimidinamines as neuroprotectants)
RN 397850-40-7 CAPLUS
CN 1,4-Benzenediamine, N-(2-aminoethyl)-N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl- (9CI) (CA INDEX NAME)



IT 397851-04-6
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of 4-pyrimidinamines as neuroprotectants)
RN 397851-04-6 CAPLUS
CN Ethanol, 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]- (CA INDEX NAME)



IT 397850-34-9P 397850-35-0P 397850-36-1P
397850-37-2P 397850-38-3P 397850-39-4P
397850-41-8P 397850-42-9P 397850-43-0P
397850-44-1P 397850-45-2P 397850-46-3P
397850-47-4P 397850-48-5P 397850-49-6P
397850-50-9P 397850-51-0P 397850-52-1P
397850-53-2P 397850-54-3P 397850-55-4P
397850-56-5P 397850-57-6P 397850-58-7P
397850-59-8P 397850-60-1P 397850-61-2P
397850-62-3P 397850-63-4P 397850-64-5P
397850-65-6P 397850-66-7P 397850-67-8P
397850-68-9P 397850-69-0P 397850-70-3P
397850-71-4P 397850-72-5P 397850-73-6P
397850-74-7P 397850-75-8P 397850-76-9P
397850-77-0P 397850-78-1P 397850-79-2P
397850-80-5P 397850-81-6P 397850-82-7P
397850-83-8P 397850-84-9P 397850-85-0P
397850-86-1P 397850-87-2P 397850-88-3P
397850-89-4P 397850-90-7P 397850-91-8P
397850-92-9P 397850-93-0P 397850-94-1P
397850-95-2P 397850-96-3P 397850-97-4P
397850-98-5P 397850-99-6P 397851-00-2P

10/513699


397851-01-3P 397851-02-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397850-34-9 CAPLUS

CN Benzamide, N-[2-[[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]amino]-1-methyl-2-oxoethyl]-
(CA INDEX NAME)




RN 397850-35-0 CAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]hexahydro-2-oxo-,
(3aS,4S,6aR)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



10/513699



RN 397850-36-1 CAPLUS

CN Hexadecanamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]- (CA INDEX NAME)




RN 397850-37-2 CAPLUS

CN Butanamide, N-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[4-[ethyl[2-[(1-oxobutyl)amino]ethyl]amino]phenyl]- (CA INDEX NAME)



RN 397850-38-3 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(cyclohexylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-39-4 CAPLUS


CN Alanine, N-benzoyl-, 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl ester (CA INDEX NAME)

10/513699




RN 397850-41-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(dimethylamino)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-42-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(3-methoxypropyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-43-0 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[(3-chlorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-44-1 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[(2,4-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)

10/513699




RN 397850-45-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(2-ethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-46-3 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(propylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 397850-47-4 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(2,5-difluorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-48-5 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-

10/513699


[[[(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 397850-49-6 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-phenylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-50-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[3,4-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-51-0 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[3-

<12/04/2007>

Erich Leese


10/513699

(diethylamino)propyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-52-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(4-bromo-2-pyridinyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-53-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(dimethylamino)ethyl](phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-54-3 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[butyl(phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-55-4 CAPLUS


CN 1,4-Benzenediamine, N-[2-([1,1'-biphenyl]-4-ylamino)ethyl]-N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl- (9CI) (CA INDEX NAME)

10/513699




RN 397850-56-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-furanylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-57-6 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3-iodophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-58-7 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2,2,2-trifluoroethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-59-8 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[3,4-difluorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)

10/513699




RN 397850-60-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(2-fluorophenyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-61-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(3,5-dimethyl-2-pyridinyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-62-3 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-phenylethyl)(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-63-4 CAPLUS


CN Acetamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-2-ethoxy-N-(phenylmethyl)- (CA INDEX NAME)

10/513699




RN 397850-64-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-methoxyphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-65-6 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[4-bromophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-66-7 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3,5-bis(trifluoromethyl)phenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-67-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(3-methoxyphenyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe

RN 397850-68-9 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3,4,5-trimethoxyphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-69-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(4-methoxyphenyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe

RN 397850-70-3 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(1H-imidazol-4-yl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)

10/513699




RN 397850-71-4 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[[2-(trifluoromethyl)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-72-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-73-6 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[[3-methoxyphenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-74-7 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[[3-methylphenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

10/513699




RN 397850-75-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(3,5-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-76-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(2-bromophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-77-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(4-bromophenyl)ethyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



PAGE 1-A

Br

PAGE 1-B


<12/04/2007>

Erich Leese

10/513699


RN 397850-78-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
[[4-fluorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-79-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
[(1-naphthalenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



PAGE 1-A


PAGE 2-A



10/513699


RN 397850-80-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
[(2-phenoxyethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-81-6 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
[[[4-(trifluoromethyl)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-82-7 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-
(butylamino)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-83-8 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-
[bis(phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-84-9 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
(3-pyridinylamino)ethyl]- (9CI) (CA INDEX NAME)

10/513699




RN 397850-85-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(2-methylphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-86-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(2-fluorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-87-2 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(3,4-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-88-3 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-ethyl(phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)

10/513699




RN 397850-89-4 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-90-7 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 397850-91-8 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 397850-92-9 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)

10/513699




RN 397850-93-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(hexahydro-1H-azepin-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 397850-94-1 CAPLUS



CN 1-Piperazinecarboxylic acid, 4-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 397850-95-2 CAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-, 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl ester, (3aS,4S,6aR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 397850-96-3 CAPLUS

CN Ethanol, 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]-, benzoate (ester) (9CI) (CA INDEX NAME)



RN 397850-97-4 CAPLUS


CN Benzeneacetamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-α-chloro- (CA INDEX NAME)



10/513699


RN 397850-98-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-6-nitro- (CA INDEX NAME)




RN 397850-99-6 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]- (CA INDEX NAME)



RN 397851-00-2 CAPLUS


CN Benzamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-4-butoxy- (CA INDEX NAME)



RN 397851-01-3 CAPLUS


CN Benzamide, N-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[4-[ethyl[2-[[4-(trifluoromethyl)benzoyl]amino]ethyl]amino]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)

10/513699



RN 397851-02-4 CAPLUS

CN Benzamide, N-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[4-[ethyl[2-[(3-fluorobenzoyl)amino]ethyl]amino]phenyl]-3-fluoro- (CA INDEX NAME)




IT 397851-07-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397851-07-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




IT 397851-03-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397851-03-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-(2-chloroethyl)-N-ethyl- (9CI) (CA INDEX NAME)

10/513699



<12/04/2007>

Erich Leese

L29 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:903173 CAPLUS

DOCUMENT NUMBER: 143:219295

TITLE: Organic electroluminescent device

INVENTOR(S): Matsuura, Masahide; Hosokawa, Chishio; Iwakuma, Toshihiro; Yamamichi, Keiko

PATENT ASSIGNEE(S): Idemitsu Kosan Co., Ltd., Japan

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079118	A1	20050825	WO 2005-JP1802	20050208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1718122	A1	20061102	EP 2005-709854	20050208
R: BE, DE, FR, GB, NL				
CN 1918946	A	20070221	CN 2005-80004202	20050208
US 20070159083	A1	20070712	US 2007-588786	20070119
PRIORITY APPLN. INFO.:			JP 2004-36051	A 20040213
			WO 2005-JP1802	W 20050208

AB The invention relates to an organic electroluminescent device comprising a plurality of light-emitting layers between cathodes and an anode, where each of the light-emitting layers contains a host material having a triplet energy gap of not less than 2.52 eV and not more than 3.7 eV and a luminescent dopant with triplet contribution which is composed of a metal complex having a heavy metal.

IT 862423-40-3 862424-73-5


RL: DEV (Device component use); USES (Uses)

(organic electroluminescent device)

RN 862423-40-3 CAPLUS


CN 9H-Carbazole, 9,9'-[5'-(2,6-diphenyl-4-pyrimidinyl)[1,1':3',1''-terphenyl]-4,4''-diyl]bis- (CA INDEX NAME)

10/513699



RN 862424-73-5 CAPLUS

CN 9H-Carbazole, 9,9'-[5'-(2-phenyl-6-(2-pyridinyl)-4-pyrimidinyl)[1,1':3',1''-terphenyl]-4,4''-diyl]bis- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


<12/04/2007>

Erich Leese

L29 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:823992 CAPLUS
 DOCUMENT NUMBER: 143:219260
 TITLE: Organic electroluminescent device
 INVENTOR(S): Matsuura, Masahide; Iwakuma, Toshihiro; Yamamichi, Keiko; Hosokawa, Chishio
 PATENT ASSIGNEE(S): Idemitsu Kosan Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005076669	A1	20050818	WO 2005-JP1799	20050208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1718121	A1	20061102	EP 2005-709851	20050208
R: BE, DE, FR, GB, NL				
CN 1918947	A	20070221	CN 2005-80004332	20050208
US 20070257600	A1	20071108	US 2007-588549	20070413
PRIORITY APPLN. INFO.:			JP 2004-32542	A 20040209
			WO 2005-JP1799	W 20050208
AB	Disclosed is an organic EL device having a multilayer structure wherein at least a light-emitting layer and an electron transport layer are arranged between cathodes and an anode is characterized in that the host material constituting the light-emitting layer has a triplet energy gap (EgT) of not less than 2.52 eV and not more than 3.7 eV, an electron-transporting material constituting the electron transport layer is different from the host material and has a hole transporting ability, and the light-emitting layer further contains a metal complex compound having phosphorescence and containing a heavy metal.			
IT	862423-40-3 862423-42-5 RL: DEV (Device component use); USES (Uses) (organic electroluminescent device)			
RN	862423-40-3 CAPLUS			
CN	9H-Carbazole, 9,9'-[5'-(2,6-diphenyl-4-pyrimidinyl)[1,1':3',1''-terphenyl]-4,4''-diyl]bis- (CA INDEX NAME)			

10/513699



RN 862423-42-5 CAPLUS

CN 9H-Carbazole, 9-[3'-(2,6-diphenyl-4-pyrimidinyl)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




REFERENCE COUNT:

13

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/513699


L29 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:636143 CAPLUS
DOCUMENT NUMBER: 143:205790
TITLE: 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: Highly potent, orally active, adenosine A2A antagonists. Part 1
AUTHOR(S): Matasi, Julius J.; Caldwell, John P.; Zhang, Hongtao; Fawzi, Ahmad; Cohen-Williams, Mary E.; Varty, Geoffrey B.; Tulshian, Deen B.
CORPORATE SOURCE: Department of Medicinal Chemistry-CV & CNS, Schering-Plough Research Institute, Kenilworth, NJ, 07033, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(16), 3670-3674
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:205790
GI



AB The structure-activity relationship of this novel class of compds. based on 2-(2-furanyl)-7-phenyl[1,2,4]-triazolo[1,5-c]pyrimidin-5-amine and its analogs was evaluated for their in vitro and in vivo adenosine A2A receptor antagonism. Several compds. displayed oral activity at 3 mg/kg in a rat catalepsy model. Specifically, compound (I) displayed an excellent in vitro profile, as well as a highly promising in vivo profile.

IT 862168-19-2P 862168-42-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(furanyl-triazolopyrimidin analogs as highly potent, orally active, adenosine A2A antagonists)


RN 862168-19-2 CAPLUS
CN 2-Pyrimidinamine, 4-[1,1'-biphenyl]-3-yl-6-chloro- (CA INDEX NAME)



10/513699

RN 862168-42-1 CAPLUS

CN 2-Furancarboxylic acid, 2-(2-amino-6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)hydrazide (CA INDEX NAME)



REFERENCE COUNT:

21

THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:540732 CAPLUS

DOCUMENT NUMBER: 143:86370

TITLE: Organic compounds having low symmetry for electroluminescent device

INVENTOR(S): Iwakuma, Toshihiro; Tomita, Seiji; Ito, Mitsunori

PATENT ASSIGNEE(S): Idemitsu Kosan Co., Ltd., Japan

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005057987	A1	20050623	WO 2004-JP18960	20041213
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1696708	A1	20060830	EP 2004-807317	20041213
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1895004	A	20070110	CN 2004-80037470	20041213
IN 2006CN02124	A	20070706	IN 2006-CN2124	20060615
US 20070104976	A1	20070510	US 2007-582963	20070105
PRIORITY APPLN. INFO.:			JP 2003-417066	A 20031215
			WO 2004-JP18960	W 20041213

AB Disclosed is a material for organic electroluminescent devices which is composed of a compound having a specific structure which is low in symmetry. An organic electroluminescent device comprising an organic thin film layer which

is composed of one or more layers including at least a light-emitting layer and sandwiched between an anode and a cathode is also disclosed wherein at least one layer of the organic thin film layer contains the above-described material for organic electroluminescent devices. The material for organic electroluminescent devices enables to obtain an organic electroluminescent device which is free from pixel defects and has a high luminous efficiency, excellent heat resistance and long life.


IT 854952-57-1P

RL: DEV (Device component use); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(organic compds. having low symmetry for electroluminescent device)

RN 854952-57-1 CAPLUS

CN 9H-Carbazole, 9,9'-(5''-(2,6-diphenyl-4-pyrimidinyl)[1,1':3',1'':3'',1''':3''',1''''-quinquephenyl]-4,4''''-diyl]bis- (9CI) (CA INDEX NAME)

10/513699



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

<12/04/2007>


Erich Leese

10/513699

L29 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:523452 CAPLUS
DOCUMENT NUMBER: 143:59997
TITLE: Preparation of 2-aminopyrimidine derivatives as
histamine H4 antagonists for the treatment of asthma
INVENTOR(S): Sato, Hiroki; Tanaka, Kazuho; Shimazaki, Makoto;
Urbahns, Klaus; Sakai, Katsuya; Gantner, Florian;
Bacon, Kevin
PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005054239	A1	20050616	WO 2004-EP13322	20041124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2003-28102 A 20031205
OTHER SOURCE(S): CASREACT 143:59997; MARPAT 143:59997
GI



AB Title compds. I [R¹ = bicyclic fused pyrrolidine, 4-aminoazetidiny], etc.; R² = H, halo, alkyl; R³ = (hetero)aryl] are prepared For instance, 4-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-6-phenylpyrimidin-2-amine dihydrochloride is prepared in 3 steps from 2-amino-4,6-dichloropyrimidine, (4aR,7aR)-octahydro-1H-pyrrolo[3,4-b]pyridine and phenylboronic acid. In assays of histamine H4 antagonism, example compds. have IC₅₀ in the range of 20 - 500 nM. I are useful in the treatment of asthma, rhinitis, allergic diseases, chronic obstructed pulmonary disease (COPD), atherosclerosis, rheumatoid arthritis, thromboembolic diseases or disorders and urol. diseases or disorders.

IT 854036-93-4P

10/513699


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-aminopyrimidine derivs. as histamine H4 antagonists for treatment of asthma)

RN 854036-93-4 CAPLUS

CN 2-Pyrimidinamine, 4-[1,1'-biphenyl]-3-yl-6-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-, hydrochloride (1:3) (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:116083 CAPLUS

DOCUMENT NUMBER: 142:198092

TITLE: A preparation of 2-aminopyrimidine derivatives, useful as histamine H4 receptor antagonists

INVENTOR(S): Sato, Hiroki; Fukushima, Keiko; Shimazaki, Makoto; Urbahns, Klaus; Sakai, Katsuya; Gantner, Florian; Bacon, Kevin

PATENT ASSIGNEE(S): Bayer Healthcare AG, Germany

SOURCE: Eur. Pat. Appl., 38 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1505064	A1	20050209	EP 2003-17810	20030805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
WO 2005014556	A1	20050217	WO 2004-EP8225	20040723
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1654237	A1	20060510	EP 2004-763418	20040723
R: DE, ES, FR, GB, IT				
PRIORITY APPLN. INFO.:			EP 2003-17810	A 20030805
			WO 2004-EP8225	W 20040723
OTHER SOURCE(S):			CASREACT 142:198092; MARPAT 142:198092	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of novel 2-aminopyrimidine derivs. of formula I [wherein: R1 is pyrrolidine or piperazine derivative attached to the pyrimidine ring via nitrogen atom; R2 is Ph or naphthyl derivative], useful as histamine H4 receptor antagonists. The 2-aminopyrimidine derivs. of the present invention are useful for treatment and prophylaxis of diseases such as asthma, rhinitis, allergic diseases, chronic obstructed pulmonary disease (CORD), atherosclerosis, and rheumatoid arthritis. For instance, 2-aminopyrimidine derivative II•3HCl was prepared via amination of 2-amino-4,6-dichloropyrimidine by aminopyrrolidine derivative III, phenylation of the obtained amino(aminopyrrolidinyl)pyrimidine derivative by PhB(OH)₂, and subsequent N-cleavage (yields: amination - 66%, phenylation - 89%). For instance, IC₅₀ for the invention compound IV•3HCl was < 20 nM.

10/513699

IT 838872-08-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of 2-aminopyrimidine derivs. useful as histamine H4 receptor
antagonists)
RN 838872-08-5 CAPLUS
CN 2-Pyrimidinamine, 4-[1,1'-biphenyl]-3-yl-6-(4-methyl-1-piperazinyl)-,
hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/513699

L29 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:817651 CAPLUS

DOCUMENT NUMBER: 141:332206

TITLE: Preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers

INVENTOR(S): Chakravarty, Prasun K.; Fisher, Michael H.; Parsons, William H.; Liang, Jun; Zhou, Bishan

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004084824	A2	20041007	WO 2004-US8532	20040319
WO 2004084824	A3	20050331		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004224392	A1	20041007	AU 2004-224392	20040319
CA 2519677	A1	20041007	CA 2004-2519677	20040319
EP 1608622	A2	20051228	EP 2004-757920	20040319
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
CN 1791580	A	20060621	CN 2004-80013599	20040319
JP 2006521357	T	20060921	JP 2006-507395	20040319
IN 2005DN04098	A	20070831	IN 2005-DN4098	20050912
US 20060293339	A1	20061228	US 2005-550641	20050923
PRIORITY APPLN. INFO.:			US 2003-456312P	P 20030324
			WO 2004-US8532	A 20040319

OTHER SOURCE(S): MARPAT 141:332206

GI




- AB The title biaryl substituted pyridine, pyrimidine and pyrazine compds. [I or II; H-1 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; H-2 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; R4, R5 = H, alkyl, alkoxy, aryloxy, etc.; R6-R8 = H, alkyl, cycloalkyl, alkoxy, etc.] which are sodium channel blockers useful for the treatment of pain (no data), were prepared E.g., a 2-step synthesis of III, starting from 2-bromo-6-methylpyridine and 3-bromophenylboronic acid, was given. Claimed pharmaceutical compns. comprise an effective amount of the instant compds. I, either alone, or in combination with one or more therapeutically active compds., and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compds., either alone, or in combination with one or more other therapeutically active compds.
- IT 770723-58-5P 770723-59-6P 770724-99-7P
770725-00-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers for treatment or prevention of pain)
- RN 770723-58-5 CAPLUS
- CN Pyrimidine, 2-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



10/513699


RN 770723-59-6 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770724-99-7 CAPLUS

CN Pyrimidine, 4-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770725-00-3 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



IT 770723-60-9P 770723-61-0P 770723-62-1P
770723-63-2P 770723-64-3P 770723-65-4P
770723-66-5P 770723-67-6P 770723-68-7P
770723-69-8P 770723-70-1P 770723-71-2P
770723-72-3P 770723-73-4P 770723-74-5P
770723-75-6P 770723-76-7P 770723-77-8P
770723-78-9P 770723-79-0P 770723-80-3P
770723-81-4P 770723-82-5P 770723-83-6P
770723-84-7P 770723-85-8P 770723-86-9P
770723-87-0P 770723-88-1P 770723-89-2P
770723-90-5P 770723-91-6P 770723-92-7P
770723-93-8P 770723-94-9P 770723-95-0P
770723-96-1P 770723-97-2P 770723-98-3P
770723-99-4P 770724-00-0P 770724-01-1P
770724-02-2P 770724-03-3P 770724-04-4P
770724-05-5P 770724-06-6P 770724-07-7P
770724-08-8P 770724-09-9P 770724-10-2P
770724-11-3P 770724-12-4P 770724-13-5P
770724-14-6P 770724-15-7P 770724-16-8P


770724-17-9P 770724-18-0P 770724-19-1P
 770724-20-4P 770724-21-5P 770724-22-6P
 770724-23-7P 770724-24-8P 770724-25-9P
 770724-26-0P 770724-27-1P 770724-28-2P
 770724-29-3P 770724-30-6P 770724-31-7P
 770724-32-8P 770724-33-9P 770724-34-0P
 770724-35-1P 770724-36-2P 770724-37-3P
 770724-38-4P 770724-39-5P 770724-40-8P
 770724-41-9P 770724-42-0P 770724-43-1P
 770724-44-2P 770724-45-3P 770724-46-4P
 770724-47-5P 770724-48-6P 770724-49-7P
 770724-50-0P 770724-51-1P 770724-52-2P
 770724-53-3P 770724-54-4P 770724-55-5P
 770724-56-6P 770724-57-7P 770724-58-8P
 770724-59-9P 770724-60-2P 770724-61-3P
 770724-62-4P 770724-63-5P 770724-64-6P
 770724-65-7P 770724-66-8P 770724-67-9P
 770724-68-0P 770724-69-1P 770724-70-4P
 770724-71-5P 770724-72-6P 770724-73-7P
 770724-74-8P 770724-75-9P 770724-76-0P
 770724-77-1P 770724-78-2P 770724-79-3P
 770724-80-6P 770724-81-7P 770724-82-8P
 770724-83-9P 770724-84-0P 770724-85-1P
 770724-86-2P 770724-87-3P 770724-88-4P
 770724-89-5P 770724-94-2P 770724-97-5P
 770725-01-4P 770725-02-5P 770725-03-6P
 770725-04-7P 770725-05-8P 770725-06-9P
 770725-07-0P 770725-08-1P 770725-09-2P
 770725-10-5P 770725-11-6P 770725-12-7P
 770725-13-8P 770725-14-9P 770725-15-0P
 770725-16-1P 770725-17-2P 770725-18-3P
 770725-19-4P 770725-20-7P 770725-21-8P
 770725-22-9P 770725-23-0P 770725-24-1P
 770725-25-2P 770725-26-3P 770725-27-4P
 770725-28-5P 770725-29-6P 770725-30-9P
 770725-31-0P 770725-32-1P 770725-33-2P
 770726-82-4P 770727-12-3P 770727-13-4P
 770727-14-5P 770727-15-6P 770727-16-7P
 770727-17-8P 770727-18-9P 770727-19-0P
 770727-20-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of biaryl substituted 6-membered heterocycles as sodium channel
 blockers for treatment or prevention of pain)

RN 770723-60-9 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-
 (CA INDEX NAME)



10/513699


RN 770723-61-0 CAPLUS

CN Pyrimidine, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-62-1 CAPLUS

CN 2,2'-Bipyrimidine, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-63-2 CAPLUS

CN Pyrimidine, 2-(methylthio)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-64-3 CAPLUS

CN Pyrimidine, 2-(methylsulfonyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-65-4 CAPLUS

CN Pyrimidine, 2-(methylsulfinyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




10/513699




RN 770723-66-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-67-6 CAPLUS

CN Methanesulfonamide, N-[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 770723-68-7 CAPLUS


CN Methanesulfonamide, N-(methanesulfonyl)-N-[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 770723-69-8 CAPLUS


CN Propanamide, 2,2-dimethyl-N-[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]- (CA INDEX NAME)

10/513699




RN 770723-70-1 CAPLUS

CN 2-Pyrimidinecarboxamide, N-methoxy-N-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-71-2 CAPLUS

CN Methanone, 4-morpholinyl[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]- (CA INDEX NAME)




RN 770723-72-3 CAPLUS

CN Ethanone, 1-[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 770723-73-4 CAPLUS

CN Alanine, 2-methyl-N-[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]carbonyl]-, methyl ester (CA INDEX NAME)




<12/04/2007>

Erich Leese

10/513699


RN 770723-74-5 CAPLUS

CN 2-Pyrimidinecarboxamide, N-(2-cyanoethyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-75-6 CAPLUS

CN Alanine, 2-methyl-N-[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]carbonyl]- (CA INDEX NAME)




RN 770723-76-7 CAPLUS

CN 2-Pyrimidinecarboxamide, N-(2-amino-1,1-dimethyl-2-oxoethyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-77-8 CAPLUS


CN Methanone, 1-piperazinyl[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 770723-78-9 CAPLUS


CN 2-Pyrimidinecarboxamide, N-2H-tetrazol-5-yl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770723-79-0 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)




RN 770723-80-3 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]carbonyl]amino]- (CA INDEX NAME)



RN 770723-81-4 CAPLUS


CN 2-Pyrimidinecarboxamide, N-[1-(aminocarbonyl)cyclopropyl]-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-82-5 CAPLUS


CN 2-Pyrimidinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770723-83-6 CAPLUS

CN 2-Pyrimidinecarboxamide, N-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-84-7 CAPLUS

CN 2-Pyrimidinecarboxamide, N,N-dimethyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-85-8 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)




RN 770723-86-9 CAPLUS

CN 2-Pyrimidinecarboxamide, N-[(1S)-2-amino-1-methyl-2-oxoethyl]-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 770723-87-0 CAPLUS

CN 2-Pyrimidinecarboxamide, N-[2-(1-piperidiny)ethyl]-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-88-1 CAPLUS

CN 2-Pyrimidinecarboxamide, N-(1,1-dimethylethyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-89-2 CAPLUS

CN 2-Pyrimidinecarboxamide, N-[(1R)-2-amino-1-methyl-2-oxoethyl]-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 770723-90-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]carbonyl]- (CA INDEX NAME)



RN 770723-91-6 CAPLUS


CN Pyrimidine, 2,5-dimethyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-92-7 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 5-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770723-93-8 CAPLUS

CN 2-Pyrimidinecarboxamide, 5-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-94-9 CAPLUS

CN 2-Pyrimidinecarboxamide, N-(2-amino-2-oxoethyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-95-0 CAPLUS

CN Pyrimidine, 5-chloro-2-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-96-1 CAPLUS

<12/04/2007>

Erich Leese


10/513699

CN 2-Pyrimidinecarboxamide, 5-chloro-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770723-97-2 CAPLUS

CN Urea, N-[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]- (CA INDEX NAME)




RN 770723-98-3 CAPLUS

CN Pyrimidine, 2-methyl-4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770723-99-4 CAPLUS

CN Pyrimidine, 4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-00-0 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

<12/04/2007>


Erich Leese

10/513699




RN 770724-01-1 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770724-02-2 CAPLUS

CN Pyrimidine, 4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 770724-03-3 CAPLUS


CN 2(1H)-Pyrimidinethione, 4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-04-4 CAPLUS

CN Ethanethioic acid, S-[4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl] ester (CA INDEX NAME)


10/513699




RN 770724-05-5 CAPLUS
CN Pyrimidine, 2-chloro-4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-06-6 CAPLUS
CN 2-Pyrimidinecarbonitrile, 4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-07-7 CAPLUS
CN Pyrimidine, 2-(2H-tetrazol-5-yl)-4-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-08-8 CAPLUS
CN Pyrimidine, 4-[5'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)

10/513699




RN 770724-09-9 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[5'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-10-2 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[5'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-11-3 CAPLUS

CN Pyrimidine, 4-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)




<12/04/2007>

Erich Leese

10/513699


RN 770724-12-4 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-13-5 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-14-6 CAPLUS

CN 2-Pyrimidinecarboxamide, N-(2-amino-1,1-dimethyl-2-oxoethyl)-4-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-15-7 CAPLUS

CN Pyrimidine, 2-methyl-4-(2'-phenoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-16-8 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-(2'-phenoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)

<12/04/2007>


Erich Leese

10/513699




RN 770724-17-9 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(2'-phenoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-18-0 CAPLUS

CN Pyrimidine, 4-(2'-chloro[1,1'-biphenyl]-3-yl)-2-methyl- (CA INDEX NAME)



RN 770724-19-1 CAPLUS


CN Pyrimidine, 4-(3'-chloro[1,1'-biphenyl]-3-yl)-2-methyl- (CA INDEX NAME)




RN 770724-20-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(1,1-dimethylethyl)-3'-(2-methyl-4-pyrimidinyl)- (CA INDEX NAME)


10/513699




RN 770724-21-5 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 3'-(2-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 770724-22-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(1,1-dimethylethyl)-3'-(2-methyl-4-pyrimidinyl)- (CA INDEX NAME)




RN 770724-23-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 3'-(2-methyl-4-pyrimidinyl)- (CA INDEX NAME)




RN 770724-24-8 CAPLUS
CN 2-Pyrimidinecarboxylic acid, 4-[2'-[[[(1,1-dimethylethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770724-25-9 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'-[[[(1,1-dimethylethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-26-0 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-(2',3'-dichloro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-27-1 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-(2',3'-dichloro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-28-2 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-(2',3'-dichloro[1,1'-biphenyl]-3-yl)-, methyl ester (CA INDEX NAME)

10/513699




RN 770724-29-3 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2'-[[1,1-dimethylethyl]amino]sulfonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-30-6 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-31-7 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[2'-[[1,1-dimethylethyl]amino]sulfonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-32-8 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)


10/513699




RN 770724-33-9 CAPLUS
CN Pyrimidine, 4-[2'-(1,1-dimethylethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770724-34-0 CAPLUS
CN 2-Pyrimidinecarboxylic acid, 4-[2'-(1,1-dimethylethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-35-1 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[2'-(1,1-dimethylethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-36-2 CAPLUS
CN Pyrimidine, 4-[2'-(cyclopropyloxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)

10/513699




RN 770724-37-3 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2'-(cyclopropyloxy)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770724-38-4 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'-(cyclopropyloxy)[1,1'-biphenyl]-3-yl]- (CA
INDEX NAME)




RN 770724-39-5 CAPLUS

CN Pyrimidine, 2-methyl-4-[2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)



RN 770724-40-8 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-
3-yl]- (CA INDEX NAME)




<12/04/2007>

Erich Leese

10/513699


RN 770724-41-9 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-42-0 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(2'-formyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-43-1 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-44-2 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-45-3 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(3'-fluoro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)


10/513699




RN 770724-46-4 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(4'-chloro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-47-5 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(4'-fluoro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-48-6 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-49-7 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(2',3'-dimethoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)

10/513699




RN 770724-50-0 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(5'-chloro-2'-methoxy[1,1'-biphenyl]-3-yl)-
(CA INDEX NAME)




RN 770724-51-1 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(2'-methyl[1,1'-biphenyl]-3-yl)- (CA INDEX
NAME)



RN 770724-52-2 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-(3'-fluoro-2'-methyl[1,1'-biphenyl]-3-yl)- (CA
INDEX NAME)



RN 770724-53-3 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[2'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)

10/513699




RN 770724-54-4 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-55-5 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(3'-chloro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-56-6 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-(3'-ethoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-57-7 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(4'-ethoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)


10/513699




RN 770724-58-8 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(2'-fluoro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-59-9 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(2',6'-dimethyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-60-2 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-61-3 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[4'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)


10/513699




RN 770724-62-4 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(4'-acetyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-63-5 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(3'-acetyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770724-64-6 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[3'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-65-7 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-(4'-cyano[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)

10/513699




RN 770724-66-8 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[3'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770724-67-9 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(2',4'-difluoro[1,1'-biphenyl]-3-yl)- (CA
INDEX NAME)



RN 770724-68-0 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[1,1'-biphenyl]-3-yl- (CA INDEX NAME)



RN 770724-69-1 CAPLUS


CN Methanesulfonamide, N-methyl-N-[3'-(2-methyl-4-pyrimidinyl)-2-
(trifluoromethoxy)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)

10/513699




RN 770724-70-4 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[4'-[methyl(methylsulfonyl)amino]-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-71-5 CAPLUS


CN Propanamide, 2,2-dimethyl-N-[3'-(2-methyl-4-pyrimidinyl)-2-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 770724-72-6 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[4'-[(2,2-dimethyl-1-oxopropyl)amino]-2-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770724-73-7 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[4'-(2,2-dimethyl-1-oxopropyl)amino]-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-74-8 CAPLUS

CN Pyrimidine, 2-(2H-tetrazol-5-yl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-75-9 CAPLUS


CN Pyrimidine, 2-(1-methyl-1H-tetrazol-5-yl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-76-0 CAPLUS


CN Pyrimidine, 2-(2-methyl-2H-tetrazol-5-yl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770724-77-1 CAPLUS

CN Pyrimidine, 2-(1H-1,2,4-triazol-5-yl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770724-78-2 CAPLUS

CN 2-Pyrimidineacetamide, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-79-3 CAPLUS


CN 2-Pyrimidineacetonitrile, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-80-6 CAPLUS


CN 2-Pyrimidinesulfonamide, N-(1,1-dimethylethyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770724-81-7 CAPLUS

CN 2-Pyrimidinesulfonamide, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 770724-82-8 CAPLUS

CN 2-Pyrimidinesulfonamide, N-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)



RN 770724-83-9 CAPLUS


CN 2-Pyrimidinemethanol, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA
INDEX NAME)



RN 770724-84-0 CAPLUS


CN 2-Pyrimidinemethanol, α -methyl-4-[2'-(trifluoromethoxy)[1,1'-
biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770724-85-1 CAPLUS

CN Acetamide, N-[[4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 770724-86-2 CAPLUS

CN Sulfamic acid, [4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-pyrimidinyl]methyl ester (9CI) (CA INDEX NAME)



RN 770724-87-3 CAPLUS


CN 2-Pyrimidinamine, N-methyl-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770724-88-4 CAPLUS


CN 2-Pyrimidinamine, N-(1-methylethyl)-4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770724-89-5 CAPLUS

CN Pyrimidine, 4-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 770724-94-2 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 770724-97-5 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[2'-[(4-oxo-1-piperidiny)methyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-01-4 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770725-02-5 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770725-03-6 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



RN 770725-04-7 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[6-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-05-8 CAPLUS


CN Pyrimidine, 4-[6-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)

10/513699




RN 770725-06-9 CAPLUS

CN Pyrimidine, 2-methyl-4-[4-(phenylmethoxy)-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770725-07-0 CAPLUS

CN [1,1'-Biphenyl]-4-ol, 3-(2-methyl-4-pyrimidinyl)-2'-(trifluoromethoxy)- (CA INDEX NAME)



RN 770725-08-1 CAPLUS


CN Acetamide, N-[5-(2-methyl-4-pyrimidinyl)-2'-(trifluoromethoxy)[1,1'-biphenyl]-2-yl]- (CA INDEX NAME)



RN 770725-09-2 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[6-(acetamino)-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)

10/513699




RN 770725-10-5 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[6-(acetylamino)-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770725-11-6 CAPLUS

CN Pyrimidine, 4-[4-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770725-12-7 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[4-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



RN 770725-13-8 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[4-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770725-14-9 CAPLUS

CN Pyrimidine, 4-[6-bromo-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-methyl-
(CA INDEX NAME)




RN 770725-15-0 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-bromo-2'-(trifluoromethoxy)[1,1'-
biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



RN 770725-16-1 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[6-bromo-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-
yl]- (CA INDEX NAME)




RN 770725-17-2 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-bromo-2'-(trifluoromethoxy)[1,1'-
biphenyl]-3-yl]- (CA INDEX NAME)


10/513699




RN 770725-18-3 CAPLUS
CN Pyrimidine, 2-methyl-4-[2'-(trifluoromethoxy)[1,1':2',1''-terphenyl]-4'-yl]- (9CI) (CA INDEX NAME)



RN 770725-19-4 CAPLUS
CN 2-Pyrimidinecarboxylic acid, 4-[2'-(trifluoromethoxy)[1,1':2',1''-terphenyl]-4'-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 770725-20-7 CAPLUS
CN 2-Pyrimidinecarboxamide, 4-[2'-(trifluoromethoxy)[1,1':2',1''-terphenyl]-4'-yl]- (9CI) (CA INDEX NAME)




RN 770725-21-8 CAPLUS
CN Pyrimidine, 4-[6-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)

10/513699




RN 770725-22-9 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)




RN 770725-23-0 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-24-1 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[6-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-25-2 CAPLUS


CN Pyrimidine, 4-[4-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)

10/513699




RN 770725-26-3 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[4-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)




RN 770725-27-4 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[4-chloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-28-5 CAPLUS


CN Pyrimidine, 4-[6-fluoro-2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]-2-methyl- (CA INDEX NAME)



RN 770725-29-6 CAPLUS


CN 2-Pyrimidinecarboxylic acid, 4-[6-fluoro-2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)

10/513699




RN 770725-30-9 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[6-fluoro-2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770725-31-0 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[6-fluoro-2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-32-1 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[6-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770725-33-2 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[2'-fluoro-6-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770726-82-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 770727-12-3 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-amino-6-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770727-13-4 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[4'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770727-14-5 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[4'-chloro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

10/513699




RN 770727-15-6 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-(2',6'-dichloro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 770727-16-7 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[2',6'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770727-17-8 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[2',6'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 770727-18-9 CAPLUS


CN Pyrimidine, 4-[4'-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2,5-dimethyl- (CA INDEX NAME)

10/513699




RN 770727-19-0 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 4-[4'-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl-, methyl ester (CA INDEX NAME)



RN 770727-20-3 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[4'-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



L29 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:739385 CAPLUS

DOCUMENT NUMBER: 141:268179

TITLE: Long-life white-emitting organic electroluminescent devices, displays, illumination apparatus, and electric appliances therewith

INVENTOR(S): Fukuda, Mitsuhiro; Genda, Kazuo

PATENT ASSIGNEE(S): Konica Minolta Holdings, Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 577 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004253298	A	20040909	JP 2003-43860	20030221
PRIORITY APPLN. INFO.:			JP 2003-43860	20030221
OTHER SOURCE(S):	MARPAT	141:268179		

GI



AB The devices have, in their constituent layers (e.g., emitting layers, hole- or electron-transporting layers), (i) compds. represented by $X1R1C:CR2X2$ [$X1, X2$ = aryl, heterocycle; $R1, R2$ = aryl, heterocyclic hydrocarbyl, cycloalkoxy ($R1 = R2$ = aryl)], $R11R12R13R14R15P$ ($R11-R15$ = monovalent substituent), $Ar2Ar1C6H4(m-Ar1Ar2)$ [$Ar1$ = bivalent aromatic hydrocarbylene; $Ar2$ = (substituted) Ph; H atom on the benzene ring may be substituted with (cyclo)alkyl, alkoxy, or halo], $Z(ArQ)n$ [Q = (substituted) o-(2-pyridyl)phenyl; Z = n-valent bridging group, single bond; Ar = bivalent arylene; $n = 2-8$], etc., (ii) fluorescent compds. with mol. weight 500-2000 and atomic ratio $F/(F + H)$ 0-0.9 and having fluorescent peak at ≤ 415 nm, (iii) polysilanes $(R21R22Si)n$ [$R21, R22$ = alkyl(oxy), aromatic group, aryloxy; $n1 \geq 3$] or $[R31(Ar31NR32R33)Si]n$ [$R31$ = alkyl(oxy), aromatic group, aryloxy; $R32, R33$ = alkyl, aromatic group; $Ar31$ = arylene; $n2 \geq 3$], and/or (iv) fluorescent compds. satisfying atomic ratio N/C 0-0.05. The devices, having phosphorescent dopants I ($Z11$ = aromatic azacycle; $Z12$ = nonarom. ring, 5-membered aromatic ring, azulene; M = metal), II ($Z21, Z22$ = aromatic azacycle; M = metal), or III ($Z41$ = azacycle; $Z42$ = ring; M = metal) in emitting layers, are also claimed. The devices exhibit high luminescent efficiency and substantially white emission, and are suited for light source uses, especially of LCD.

IT 650606-89-6


RL: DEV (Device component use); USES (Uses)

10/513699

(long-life white-emitting organic LED containing azacyclic phosphorescent
dopants and showing high luminescent efficiency)

RN 650606-89-6 CAPLUS

CN Pyrimidine, 2,4,6-tris([1,1':3',1''-terphenyl]-5'-yl)- (9CI) (CA INDEX
NAME)




10/513699

L29 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:78016 CAPLUS
DOCUMENT NUMBER: 140:136202
TITLE: Organic electroluminescent device and display
INVENTOR(S): Matsuura, Mitsunobu; Yamada, Taketoshi; Kita, Hiroshi
PATENT ASSIGNEE(S): Konica Minolta Holdings Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 34 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004031004	A	20040129	JP 2002-182682	20020624
JP 4036041	B2	20080123		
JP 2007335904	A	20071227	JP 2007-233744	20070910
PRIORITY APPLN. INFO.:			JP 2002-182682	A3 20020624
OTHER SOURCE(S):	MARPAT	140:136202		
GI				




AB The invention relates to an organic electroluminescent device, suited for use in making an optical display, comprising a phosphorescent substance-containing host layer as a light-emitting layer, wherein the electron transporting layer or the light-emitting layer contains the compound represented by I [R11-14 = H and monovalent group; at least one of R11-14 is bonded to the pyrimidine skeleton through C, O, S, and Si atoms], and the phosphorescent substance is iridium, osmium and platinum compds.

IT 650606-89-6 650606-90-9
RL: DEV (Device component use); USES (Uses)
(organic electroluminescent device with phosphorescent light-emitting layer)

RN 650606-89-6 CAPLUS


CN Pyrimidine, 2,4,6-tris([1,1':3',1''-terphenyl]-5'-yl)- (9CI) (CA INDEX NAME)

10/513699



RN 650606-90-9 CAPLUS

CN Pyrimidine, 2,4,6-tris(2,2'',3,3'',4,4'',5,5'',6,6''-decafluoro[1,1':3',1''-terphenyl]-5'-yl)- (9CI) (CA INDEX NAME)



L29 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:300895 CAPLUS

DOCUMENT NUMBER: 138:321288

TITLE: Preparation of 2- and 4-aminopyrimidines N-substituted by a bicyclic ring for use as kinase inhibitors in the treatment of cancer

INVENTOR(S): Nagarathnam, Dhanapalan; Wang, Chunguang; Chen, Yuanwei; Yi, Lin; Chen, Jianqing; Weber, Olaf; Boyer, Stephen; Clark, Roger B.; Phillips, Barton; Meahl, Jennifer; Ladouceur, Gaetan; Bi, Cheng; Burke, Michael J.; Cook, James; Verma, Sharad K.; Fan, Jianmei

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: PCT Int. Appl., 118 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003030909	A1	20030417	WO 2002-US30616	20020925
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002330108	A1	20030422	AU 2002-330108	20020925
PRIORITY APPLN. INFO.:			US 2001-324276P	P 20010925
			US 2002-352509P	P 20020131
			WO 2002-US30616	W 20020925

OTHER SOURCE(S): MARPAT 138:321288

GI



AB The title compds. [I; X = NR₁R₆, NR₄R₅, R₄, with the proviso that at least one X must be NR₁R₆; R₁ = (un)substituted fused bicyclic unsatd. ring containing 9 or 10 atoms optionally containing 1-4 heteroatoms selected from the group consisting of N, S and O; R₂ = H, halo, alkyl, etc.; R₃ = H, alkyl, thio; R₄ = (un)substituted -Y_n-mono-ring group or -Y_n-multi-ring group (each ring containing 4-18 atoms in the ring and optionally containing 1-4 heteroatoms selected from N, S, and O; n = 0-1; Y = alkylene, C(CN); R₄

can also be hydrogen or alkyl when R5 is present); R5 = (un)substituted -Yn-mono-ring group or -Yn-multi-ring group (each ring containing 4-18 atoms in the ring and optionally containing 1-4 heteroatoms selected from N, S, and O; n = 0-1; Y = alkylene, N:CH, N:CHMe; with the proviso that the multi-ring group cannot be benzimidazolyl); R6 = H, alkyl] which are kinase inhibitors useful in the treatment of cancer and viral infections, were prepared and formulated. Thus, heating 6-aminoquinoline with 2,4-dichloro-5-trifluoromethylpyrimidine (preparation given) in the presence of Na2CO3 in BuOH to 120°C for 3 days afforded I [X = 6-quinolinylamino; R2 = CF3; R3 = H] which showed IC50 of 0.48 µM in in vitro proliferation inhibition assay (HCT 116 human colorectal carcinoma cells).


IT 511248-79-6P 511249-01-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2- and 4-aminopyrimidines as kinase inhibitors in the treatment of cancer)


RN 511248-79-6 CAPLUS

CN 6-Quinolinamine, N-(4-[1,1'-biphenyl]-3-yl-5-fluoro-2-pyrimidinyl)- (CA INDEX NAME)



RN 511249-01-7 CAPLUS

CN 1H-Indazol-5-amine, N-(4-[1,1'-biphenyl]-3-yl-5-fluoro-2-pyrimidinyl)-1-methyl- (CA INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/513699

L29 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:927396 CAPLUS

DOCUMENT NUMBER: 138:13955

TITLE: Preparation of phenol and hydroxynaphthalene based inhibitors of protein kinase for the treatment of disease

INVENTOR(S): Cao, Sheldon Xiaodong; Bounaud, Pierre-Yves; Chen, Xiaohua; Chung, Hyun-Ho; Dumas, David Paul; Kc, Sunil Kumar; Min, Changhee; Yang, Jae Young; Long, Mellissa C.

PATENT ASSIGNEE(S): LG Biomedical Institute, USA

SOURCE: PCT Int. Appl., 286 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096867	A2	20021205	WO 2002-US16920	20020528
WO 2002096867	A3	20040304		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002310187	A1	20021209	AU 2002-310187	20020528
US 20030187007	A1	20031002	US 2002-158030	20020528
US 20030208067	A1	20031106	US 2002-158103	20020528
EP 1412327	A2	20040428	EP 2002-737248	20020528
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004534779	T	20041118	JP 2003-500047	20020528
KR 2004026657	A	20040331	KR 2003-715388	20031125
PRIORITY APPLN. INFO.:			US 2001-294792P	P 20010530
			WO 2002-US16920	W 20020528

OTHER SOURCE(S): MARPAT 138:13955

GI



AB Phenol and hydroxynaphthalene derivs. I [X = O, S, amine, alkylamine, alkynylamine, arylamine, and heteroarylamine; R1 = (un)substituted 5- or 6-membered aromatic or heteroarom. ring, -(X1)_mCOX2-, wherein X1 = alkylene, alkenylene, alkynylene, aryl and heteroaryl, X2 = H, alkyl, aryl, heteroaryl, OH, alkoxy, amino, substituted amine, m = 0 or 1, or R1 = -C(X3)=N-NX4-C(=E)-NX5X6 wherein X3 = H, alkyl, aryl, alkylaryl, heteroaryl, and amino and E = O, S, and substituted amine with X4, X5, and X6 independently equal to H, alkyl, aryl, and heteroaryl; R2, R3, and R4 = H, alkyl, alkylene, halo, alkoxy, etc.; or R2 and R3 or R3 and R4 may be taken together to form an (un)substituted aromatic or heteroarom. ring; R5 = H, (un)substituted-alkyl, -aryl, -heterocycle, etc.; R6 = H, alkyl, alkene, alkyne, aryl, and heteroaryl] are prepared and disclosed as inhibitors of protein kinase. Thus, II was prepared by cyclocondensation of 5'-bromo-2'-methoxyacetophenone with N,N-dimethylformamide di-Et acetal with subsequent Suzuki coupling with 4-methoxyphenylboronic acid. In assays to determine cyclin dependent kinase activity, specifically against CDK2 and CDK5, II possessed IC₅₀ values of 0-0.5 μM. II proved highly specific for CDK2 and CDK5 and was further evaluated by in vitro tumor cell efficacy tests against numerous cancers. The present invention is directed in part towards methods of modulating the function of protein kinases with phenol- and hydroxynaphthalene-based compds. The methods incorporate cells that express a protein kinase. In addition, the invention describes methods of preventing and treating protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to phenol- and hydroxynaphthalene-based compds. and pharmaceutical compns. comprising these compds.


IT 477726-63-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of phenol and hydroxynaphthalene based inhibitors of protein kinase)

RN 477726-63-9 CAPLUS

10/513699

CN [1,1'-Biphenyl]-4,4'-diol, 3-(2-amino-6-chloro-4-pyrimidinyl)- (CA INDEX NAME)




IT 477726-56-0P 477726-59-3P 477726-61-7P
477726-62-8P 477726-64-0P 477726-65-1P
477726-66-2P 477726-86-6P 477726-87-7P
477726-88-8P 477726-89-9P 477726-90-2P
477726-91-3P 477726-92-4P 477726-93-5P
477726-94-6P 477726-95-7P 477726-96-8P
477726-97-9P 477726-98-0P 477726-99-1P
477727-00-7P 477727-03-0P 477727-05-2P
477727-06-3P 477727-07-4P 477727-08-5P
477727-09-6P 477727-10-9P 477727-11-0P
477727-12-1P 477727-13-2P 477727-14-3P
477727-15-4P 477727-16-5P 477727-17-6P
477727-18-7P 477727-19-8P 477727-20-1P
477727-21-2P 477727-22-3P 477727-23-4P
477727-24-5P 477727-25-6P 477727-26-7P
477727-27-8P 477727-28-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenol and hydroxynaphthalene based inhibitors of protein kinase)

RN 477726-56-0 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-(2-amino-6-methyl-4-pyrimidinyl)- (CA INDEX NAME)




RN 477726-59-3 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-(2-amino-6-methoxy-4-pyrimidinyl)- (CA INDEX NAME)


10/513699




RN 477726-61-7 CAPLUS
CN [1,1'-Biphenyl]-4,4'-diol, 3-(2,6-diamino-4-pyrimidinyl)- (CA INDEX NAME)



RN 477726-62-8 CAPLUS
CN [1,1'-Biphenyl]-4,4'-diol, 3-(2-amino-4-pyrimidinyl)-3'-fluoro- (CA INDEX NAME)




RN 477726-64-0 CAPLUS
CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(2-hydroxyethyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 477726-65-1 CAPLUS
CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(2,3-dihydroxypropyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)

10/513699




RN 477726-66-2 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-(2-amino-4-pyrimidinyl)- (CA INDEX NAME)




RN 477726-86-6 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(5-hydroxypentyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 477726-87-7 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-(1-piperazinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 477726-88-8 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/513699



RN 477726-89-9 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 477726-90-2 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-(4-morpholinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 477726-91-3 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[3-(hydroxymethyl)-1-piperidinyl]-4-pyrimidinyl]- (CA INDEX NAME)

<12/04/2007>


Erich Leese

10/513699




RN 477726-92-4 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 477726-93-5 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 477726-94-6 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[4-(hydroxymethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 477726-95-7 CAPLUS

10/513699

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[(1R)-1-(hydroxymethyl)-2-phenylethyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 477726-96-8 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 477726-97-9 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-(3-nitrophenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 477726-98-0 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-(4-nitrophenyl)-4-pyrimidinyl]- (CA INDEX NAME)


10/513699




RN 477726-99-1 CAPLUS
CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-(4-aminophenyl)-4-pyrimidinyl]-
(CA INDEX NAME)



RN 477727-00-7 CAPLUS
CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-(3-aminophenyl)-4-pyrimidinyl]-
(CA INDEX NAME)



RN 477727-03-0 CAPLUS
CN [1,1'-Biphenyl]-4-ol, 3'-amino-3-(2-amino-4-pyrimidinyl)- (CA INDEX NAME)




RN 477727-05-2 CAPLUS
CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[[(1R)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]amino]-4-pyrimidinyl]-
(CA INDEX NAME)

Absolute stereochemistry.

<12/04/2007>

Erich Leese


10/513699



RN 477727-06-3 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(1S)-2-hydroxy-1-phenylethyl]amino]-4-pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 477727-07-4 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(4-methoxyphenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 477727-08-5 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(1S)-1-(hydroxymethyl)-2-[(phenylmethyl)thio]ethyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 477727-09-6 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[2-(1H-indol-3-yl)ethyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 477727-10-9 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[4-(phenylmethyl)-1-piperazinyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 477727-11-0 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[2-(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/513699



RN 477727-12-1 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[1S]-1-(hydroxymethyl)-2-methylpropyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 477727-13-2 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-(4-methyl-1-piperazinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 477727-14-3 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

10/513699




RN 477727-15-4 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[2-(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 477727-16-5 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-(4-thiomorpholinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 477727-17-6 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[[1,1'-biphenyl]-2-ylmethyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 477727-18-7 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(3-chlorophenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)

10/513699




RN 477727-19-8 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(4-chlorophenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 477727-20-1 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(3-methoxyphenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 477727-21-2 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(1R)-2-hydroxy-1-phenylethyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 477727-22-3 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-(3-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)

<12/04/2007>

Erich Leese


10/513699

INDEX NAME)




RN 477727-23-4 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-(1H-indol-5-yl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 477727-24-5 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[3-(3-fluorophenyl)methyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 477727-25-6 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[2-(2-fluorophenyl)methyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 477727-26-7 CAPLUS

<12/04/2007>

Erich Leese


10/513699

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[(3-methoxyphenyl)methyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 477727-27-8 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[(4-methoxyphenyl)methyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 477727-28-9 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(2-fluoro-4-hydroxyphenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)



IT 477727-42-7P 477727-45-0P 477727-47-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of phenol and hydroxynaphthalene based inhibitors of protein kinase)

RN 477727-42-7 CAPLUS


CN 2-Pyrimidinamine, 4-[4,4'-bis (phenylmethoxy) [1,1'-biphenyl]-3-yl]-6-methyl- (CA INDEX NAME)

10/513699




RN 477727-45-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4,4'-bis(phenylmethoxy)[1,1'-biphenyl]-3-yl]-6-methoxy- (CA INDEX NAME)



RN 477727-47-2 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[4,4'-bis(phenylmethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



10/513699

L29 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:122964 CAPLUS

DOCUMENT NUMBER: 136:167384

TITLE: Preparation of 4-pyrimidinamines as neuroprotectants.

INVENTOR(S): Grant, Elfrida R.; Brown, Frank K.; Zivin, Robert Allan; McMillan, Michael; Zhong, Zhong; Scott, Malcolm; Reitz, Allen B.; Ross, Tina Morgan

PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012198	A2	20020214	WO 2001-US24659	20010806
WO 2002012198	A3	20020606		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2419030	A1	20020214	CA 2001-2419030	20010806
AU 2001081120	A	20020218	AU 2001-81120	20010806
EP 1313713	A2	20030528	EP 2001-959581	20010806
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001013165	A	20030715	BR 2001-13165	20010806
JP 2004505952	T	20040226	JP 2002-518176	20010806
NZ 524100	A	20050128	NZ 2001-524100	20010806
IN 2003KN00137	A	20050311	IN 2003-KN137	20030203
MX 2003PA01226	A	20040910	MX 2003-PA1226	20030210
ZA 2003001868	A	20040625	ZA 2003-1868	20030306
PRIORITY APPLN. INFO.:			US 2000-223791P	P 20000808
			WO 2001-US24659	W 20010806

OTHER SOURCE(S): MARPAT 136:167384

GI



AB Pharmaceutical compns. comprising a pharmaceutically acceptable carrier [I; R9 = H, thienyl, furanyl, pyrrolyl, (substituted) Ph, pyridinyl,

<12/04/2007>

Erich Leese


pyridinyl, naphthyl, benzo[b]thien-2-yl, 2-benzofuranyl, pyrimidinyl, 2,4-bis(methoxyphenyl)-5-pyrimidinyl; R10 = cyanoalkyl, alkylamino, dialkylamino, hydroxyalkylamino, hydroxydialkylamino; R11 = H, alkyl], are claimed. Thus, a mixture of N-(2-aminoethyl)-N'-(6-biphenyl-3-ylpyrimidin-4-yl)-N-ethylbenzene-1,4-diamine (preparation given), N-benzoylalanine, diisopropylethylamine, HBTU, and DMF was stirred overnight at room temperature to give N-[1-[[2-[4-(6-biphenyl-3-ylpyrimidin-4-ylamino)phenyl]ethylamino]ethylcarbamoyl]ethyl]benzamide. Tested compds. in a differentiated P19 cell assay using 3 mM glutamate showed neuroprotectant activity with IC50 = 0.07 μ M to >1 μ M.

IT 397850-40-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397850-40-7 CAPLUS

CN 1,4-Benzenediamine, N-(2-aminoethyl)-N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl- (9CI) (CA INDEX NAME)




IT 397851-04-6

RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397851-04-6 CAPLUS

CN Ethanol, 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]- (CA INDEX NAME)



IT 397850-34-9P 397850-35-0P 397850-36-1P
397850-37-2P 397850-38-3P 397850-39-4P
397850-41-8P 397850-42-9P 397850-43-0P
397850-44-1P 397850-45-2P 397850-46-3P
397850-47-4P 397850-48-5P 397850-49-6P
397850-50-9P 397850-51-0P 397850-52-1P
397850-53-2P 397850-54-3P 397850-55-4P
397850-56-5P 397850-57-6P 397850-58-7P
397850-59-8P 397850-60-1P 397850-61-2P
397850-62-3P 397850-63-4P 397850-64-5P
397850-65-6P 397850-66-7P 397850-67-8P
397850-68-9P 397850-69-0P 397850-70-3P


397850-71-4P 397850-72-5P 397850-73-6P
 397850-74-7P 397850-75-8P 397850-76-9P
 397850-77-0P 397850-78-1P 397850-79-2P
 397850-80-5P 397850-81-6P 397850-82-7P
 397850-83-8P 397850-84-9P 397850-85-0P
 397850-86-1P 397850-87-2P 397850-88-3P
 397850-89-4P 397850-90-7P 397850-91-8P
 397850-92-9P 397850-93-0P 397850-94-1P
 397850-95-2P 397850-96-3P 397850-97-4P
 397850-98-5P 397850-99-6P 397851-00-2P
 397851-01-3P 397851-02-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397850-34-9 CAPLUS

CN Benzamide, N-[2-[[2-[[4-[(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl]amino]phenyl]ethylamino]ethyl]amino]-1-methyl-2-oxoethyl]- (CA INDEX NAME)





RN 397850-35-0 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl]amino]phenyl]ethylamino]ethyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A







RN 397850-36-1 CAPLUS

CN Hexadecanamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]- (CA INDEX NAME)



RN 397850-37-2 CAPLUS


CN Butanamide, N-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[4-[ethyl[2-[(1-oxobutyl)amino]ethyl]amino]phenyl]- (CA INDEX NAME)



RN 397850-38-3 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(cyclohexylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)

10/513699




RN 397850-39-4 CAPLUS

CN Alanine, N-benzoyl-, 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl ester (CA INDEX NAME)




RN 397850-41-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(dimethylamino)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-42-9 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(3-methoxypropyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-43-0 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(3-chlorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)

10/513699




RN 397850-44-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[(2,4-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-45-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[(2-ethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-46-3 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(propylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 397850-47-4 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[(2,5-difluorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)

10/513699




RN 397850-48-5 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[[(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 397850-49-6 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-phenylethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




<12/04/2007>

Erich Leese

10/513699


RN 397850-50-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[3,4-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-51-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[3-(diethylamino)propyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-52-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(4-bromo-2-pyridinyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-53-2 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(dimethylamino)ethyl](phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-54-3 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[butyl(phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)

10/513699




RN 397850-55-4 CAPLUS

CN 1,4-Benzenediamine, N-[2-([1,1'-biphenyl]-4-ylamino)ethyl]-N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-56-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-furanylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-57-6 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3-iodophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-58-7 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2,2,2-trifluoroethyl)amino]ethyl]- (9CI) (CA INDEX NAME)

10/513699




RN 397850-59-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(3,4-difluorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-60-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(2-thienyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-61-2 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(3,5-dimethyl-2-pyridinyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-62-3 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-phenylethyl)(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)

10/513699




RN 397850-63-4 CAPLUS

CN Acetamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl]amino]phenyl]ethylamino]ethyl]-2-ethoxy-N-(phenylmethyl)- (CA INDEX NAME)




RN 397850-64-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-methoxyphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-65-6 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[4-bromophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-66-7 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[[3,5-bis(trifluoromethyl)phenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)

10/513699



RN 397850-67-8 CAPLUS
CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
[[2-(3-methoxyphenyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

— OMe

RN 397850-68-9 CAPLUS
CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
[[3,4,5-trimethoxyphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-69-0 CAPLUS
CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
[[2-(4-methoxyphenyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)



— OMe


RN 397850-70-3 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(1H-imidazol-4-yl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-71-4 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[[2-(trifluoromethyl)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-72-5 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-73-6 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[[3-methoxyphenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

10/513699




RN 397850-74-7 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[(3-methylphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-75-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[(3,5-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-76-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[(2-bromophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-77-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(4-bromophenyl)ethyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)





— Br

RN 397850-78-1 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
[[4-fluorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

RN 397850-79-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
[(1-naphthalenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-80-5 CAPLUS
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
 [(2-phenoxyethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-81-6 CAPLUS
 CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
 [[[4-(trifluoromethyl)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

10/513699




RN 397850-82-7 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(butylamino)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-83-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-bis(phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-84-9 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(3-pyridinylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 397850-85-0 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(2-methylphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

10/513699




RN 397850-86-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(2-fluorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-87-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-88-3 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-ethyl(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-89-4 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10/513699




RN 397850-90-7 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-91-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 397850-92-9 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-93-0 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(hexahydro-1H-azepin-1-yl)ethyl]- (9CI) (CA INDEX NAME)

10/513699



RN 397850-94-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[4-[(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl]amino]phenyl]ethylamino]ethyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 397850-95-2 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-, 2-[[[4-[(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl]amino]phenyl]ethylamino]ethyl ester, (3aS,4S,6aR)- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




<12/04/2007>

Erich Leese




RN 397850-96-3 CAPLUS

CN Ethanol, 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]-, benzoate (ester) (9CI) (CA INDEX NAME)




RN 397850-97-4 CAPLUS

CN Benzeneacetamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]- α -chloro- (CA INDEX NAME)



RN 397850-98-5 CAPLUS


CN 3-Pyridinecarboxamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-6-nitro- (CA INDEX NAME)



RN 397850-99-6 CAPLUS


10/513699

CN [1,1'-Biphenyl]-4-carboxamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]- (CA INDEX NAME)




RN 397851-00-2 CAPLUS

CN Benzamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-4-butoxy- (CA INDEX NAME)



RN 397851-01-3 CAPLUS


CN Benzamide, N-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[4-[ethyl[2-[[4-(trifluoromethyl)benzoyl]amino]ethyl]amino]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 397851-02-4 CAPLUS

CN Benzamide, N-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[4-[ethyl[2-[(3-fluorobenzoyl)amino]ethyl]amino]phenyl]-3-fluoro- (CA INDEX NAME)

10/513699




IT 397851-07-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397851-07-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N,N-dimethyl-
(9CI) (CA INDEX NAME)




IT 397851-03-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397851-03-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-(2-
chloroethyl)-N-ethyl- (9CI) (CA INDEX NAME)



L29 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:12404 CAPLUS

DOCUMENT NUMBER: 134:71603

TITLE: Preparation of 2-(3-heterocyclylphenoxy-,
3-heterocyclylbenzyl, 3-phenylphenoxy, or
3-phenylbenzyl)-3-methoxyacrylic acid derivatives as
agrochemical fungicides and intermediates for the
preparation thereof

INVENTOR(S): Sakaguchi, Hiroshi

PATENT ASSIGNEE(S): Sumitomo Chemical Company, Limited, Japan

SOURCE: PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000562	A1	20010104	WO 2000-JP4080	20000622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001064237	A	20010313	JP 2000-189119	20000623
PRIORITY APPLN. INFO.:			JP 1999-179874	A 19990625
OTHER SOURCE(S):	MARPAT 134:71603			

GI



AB Acrylic acid derivs. represented by general formula [I; wherein W is oxygen or CH₂; X is CR₄ or nitrogen; Y is CR₅ or nitrogen; R₁, R₂ and R₃ are each independently hydrogen, halogeno, cyano, nitro, amino, hydroxyl, (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, C6-10 aryl, heteroaryl, C1-6 alkoxy, phenoxy, heteroaryloxy, C2-6 alkoxy carbonyl, C1-6 alkylthio, or C3-30 trialkylsilyl; and R₄, R₅, R₆, R₇ and R₈ are each independently hydrogen, halogeno, C1-4 alkyl, C1-4 haloalkyl, or C1-4 alkoxy] are prepared Also claimed are plant disease controllers containing the same as the active ingredient, a method for

controlling plant diseases with the derivs., and a method for preparing I. Thus, Me 2-(5-iodo-2-methylphenoxy)-3-methoxy-2-propenoate 200, 4,4,5,5-tetramethyl-2-[3-(4-pyrimidyl)phenyl]-1,3,2-dioxaborane 162, K₃PO₄.H₂O 610, [1,1'-bis(diphenylphosphono)ferrocene]dichloropalladium(II)-methylene chloride complex 23, Pd(OAc)₂ 6 mg, and 3 mL ethylene glycol di-Me ether were mixed and heated with stirring at 83° for 1.5 h to give Me 3-methoxy-2-[2-methyl-5-[3-(4-pyrimidyl)phenyl]phenoxy]-2-propenoate (II). II prevented *Pseudocercospora herpotrichoides* in wheat plants by 90% at 500 ppm.


IT 315189-11-8P

RL: ARG (Analytical reagent use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (3-heterocyclylphenoxy-, 3-heterocyclylbenzyl, phenylphenoxy, or phenylbenzyl)methoxyacrylic acid derivs. as agrochem. fungicides)

RN 315189-11-8 CAPLUS

CN 2-Propenoic acid, 3-methoxy-2-[[4-methyl-3'-(4-pyrimidinyl)[1,1'-biphenyl]-3-yl]oxy]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT:


24

THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/513699

L29 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:117033 CAPLUS
DOCUMENT NUMBER: 132:166238
TITLE: Preparation of triazolone derivatives as fungicides
for plants and intermediate therefor
INVENTOR(S): Manabe, Akio; Kinoshita, Yoshiharu; Sakaguchi,
Hiroshi; Araki, Tomohiro
PATENT ASSIGNEE(S): Sumitomo Chemical Company, Limited, Japan
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000007999	A1	20000217	WO 1999-JP4161	19990803
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2000239261	A	20000905	JP 1999-217579	19990730
CA 2339270	A1	20000217	CA 1999-2339270	19990803
AU 9949331	A	20000228	AU 1999-49331	19990803
EP 1103548	A1	20010530	EP 1999-933231	19990803
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6489487	B1	20021203	US 2001-762242	20010205
PRIORITY APPLN. INFO.:			JP 1998-218973	A 19980803
			JP 1998-310672	A 19981030
			JP 1998-370829	A 19981225
			WO 1999-JP4161	W 19990803
OTHER SOURCE(S):	MARPAT 132:166238			
GI				



AB Triazolone derivs. represented by formula (I; wherein R1 represents

optionally substituted C1-10 alkyl, C2-10 alkenyl, or C2-10 alkynyl, halo, NO₂, cyano, optionally substituted C4-20 cycloalkylalkyl, C5-10 cycloalkenyl, C6-20 cycloalkenylalkyl, C6-10 aryl, C7-20 arylalkyl, C1-9 heteroaryl, or C2-19 heteroarylalkyl, etc.; R₂ represents hydrogen or C1-6 alkyl; R₃ represents C1-6 alkoxy, C1-6 alkylthio, cyano, halo, vinyl, thenyl, cyclopropyl, or C1-6 alkyl; one of T, U, and V represents CR₄, another represents CH or nitrogen, and the remaining one represents CR₅ or nitrogen; and W represents CR₆ or nitrogen; wherein R₄ - R₆ = H, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, cyano, NO₂, C2-6 alkoxy carbonyl, C1-6 alkylthio, or C1-6 haloalkylthio) are prepared. Thus, a solution of 1,1-dimethyl-4-(3-phenylbenzyl)semicarbazide in CH₂Cl₂ was added dropwise to a solution of triphosgene in CH₂Cl₂ under ice-cooling, warmed to room temperature and then heated under reflux for 4 h to give 5-chloro-2-methyl-4-(3-phenylbenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one. The compound was dissolved in anhydrous MeOH, treated with a solution of

NaOMe,


and refluxed for 3.5 h to give 5-methoxy-2-methyl-4-(3-phenylbenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one, which at 500 ppm spray limited the infection of rice seedlings by *Piricularia oryzae* to ≤10% of the plant.

IT 258885-74-4P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of triazolone derivs. as fungicides for plants)

RN 258885-74-4 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 2,4-dihydro-5-methoxy-2-methyl-4-[[4-methyl-3'-(4-pyrimidinyl)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)



REFERENCE COUNT:

10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/513699

L29 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:98347 CAPLUS

DOCUMENT NUMBER: 133:37773

TITLE: Polyamines: agents with macrofilaricidal activity

AUTHOR(S): Kinnamon, K. E.; Engle, R. R.; Poon, B. T.; Ellis, W. Y.; Mccall, J. W.; Dzimianski, M. T.

CORPORATE SOURCE: Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Washington, DC, 20307-5100, USA

SOURCE: Annals of Tropical Medicine & Parasitology (1999), 93(8), 851-858

CODEN: ATMPA2; ISSN: 0003-4983

PUBLISHER: Carfax Publishing

DOCUMENT TYPE: Journal

LANGUAGE: English

AB There is a need for effective macrofilaricidal drugs. The polyamine metabolism of filarial worms has been recognized as a possible target for effective drug action. In an attempt to identify agents that might provide leads in developing an effective macrofilaricide, 78 polyamine compds. were selected from among > 250 000 structures that have been amassed by the Walter Reed Army Institute of Research, in the U.S.A. These thousands of agents have been chosen principally for drug-development programs for other parasitic diseases. The 78 prospective drugs selected were evaluated for their macrofilaricidal activity against *Brugia pahangi* and *Acanthocheilonema viteae*, in male Mongolian jirds (*Meriones unguiculatus*). The animal models using these two parasites were designed to mimic, in so far as possible, human lymphatic filariasis and onchocerciasis, resp. Thirteen of the compds. were found to be active although none of these has been previously reported to be macrofilaricidal. Two were suppressive for *B. pahangi* and 11 for *A. viteae*. These active agents may represent a nucleus around which highly effective drugs can be synthesized.


IT 71525-23-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(polyamines: agents with macrofilaricidal activity)

RN 71525-23-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[1,1'-biphenyl]-3-yl-5-(4-phenylbutyl)- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/513699

L29 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:295954 CAPLUS

DOCUMENT NUMBER: 131:5238

TITLE: 4-Aryl-2-anilinopyrimidines as corticotropin-releasing hormone (CRH) antagonists

AUTHOR(S): Cocuzza, Anthony J.; Hobbs, Frank W.; Arnold, Charles R.; Chidester, Dennis R.; Yarem, Jerry A.; Culp, Steven; Fitzgerald, Lawrence; Gilligan, Paul J.

CORPORATE SOURCE: Chemical and Physical Sciences Department, DuPont Pharmaceuticals Company, Wilmington, DE, 19880-0500, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(7), 1057-1062

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of 4-aryl-2-(N-ethylanilino)pyrimidines has been synthesized as corticotropin-releasing hormone inhibitors. The effect of substitution on each aromatic ring on receptor binding was investigated.


IT 225922-79-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(2-anilino-4-arylpyrimidines as corticotropin-releasing hormone antagonists)

RN 225922-79-2 CAPLUS

CN 2-Pyrimidinamine, 4-[1,1'-biphenyl]-3-yl-N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-6-methyl- (CA INDEX NAME)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1992:194345 CAPLUS
 DOCUMENT NUMBER: 116:194345
 ORIGINAL REFERENCE NO.: 116:32937a,32940a
 TITLE: Pyrimidyl-substituted acrylic acid esters
 INVENTOR(S): Klausener, Alexander; Knueppel, Peter C.; Dehne, Heinz
 Wilhelm; Dutzmann, Stefan
 PATENT ASSIGNEE(S): Bayer A.-G., Germany
 SOURCE: Eur. Pat. Appl., 65 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 471261	A1	19920219	EP 1991-113091	19910803
EP 471261	B1	19960117		
R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL				
DE 4025891	A1	19920220	DE 1990-4025891	19900816
US 5231097	A	19930727	US 1991-739647	19910802
ES 2082057	T3	19960316	ES 1991-113091	19910803
BR 9103495	A	19920512	BR 1991-3495	19910805
JP 04244068	A	19920901	JP 1991-223648	19910809
ZA 9106449	A	19920527	ZA 1991-6449	19910815
PRIORITY APPLN. INFO.:			DE 1990-4025891	A 19900816
OTHER SOURCE(S):	CASREACT 116:194345; MARPAT 116:194345			
GI				




AB PyXC(:CHR)CO2R1 (Py = pyrimidinyl; R = dialkylamino, alkoxy, aralkoxy; R1 = alkyl; X = O, S, NR2; R2 = H, alkyl, aralkyl, aryl) were prepared for use as fungicides. Thus, 4-chloro-6-(3-methoxyphenyl)pyrimidine was treated with MeNHCH2CO2Me.HCl followed by Me3COCH(NMe2)2 to give the pyrimidine I (R3 = NMe2), which was hydrolyzed with aqueous HCl and treated with Me2SO4 to give I (R3 = OMe). The latter compound was more active against *Phytophthora* on tomatoes than standard compds.
 IT 140117-37-9P 140117-47-1P 140117-99-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 140117-37-9 CAPLUS
 CN 2-Propenoic acid, 2-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)methylamino]-3-(dimethylamino)-, methyl ester (CA INDEX NAME)

10/513699




RN 140117-47-1 CAPLUS

CN 2-Propenoic acid, 2-[(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl]methylamino]-3-methoxy-, methyl ester (CA INDEX NAME)



RN 140117-99-3 CAPLUS

CN 2-Propenoic acid, 3-(dimethylamino)-2-[[4-(4'-methoxy[1,1'-biphenyl]-3-yl)-2-pyrimidinyl]methylamino]-, methyl ester (CA INDEX NAME)



L29 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:586317 CAPLUS

DOCUMENT NUMBER: 93:186317

ORIGINAL REFERENCE NO.: 93:29703a,29706a

TITLE: Heterocyclopolyaromatics. IX. 4,4'',6,6''-Tetraazahexa-m-phenylene and 4,4',4'',4'',6,6',6'',6''-octazahexa-m-phenylene

AUTHOR(S): Muke, Bernd; Kauffmann, Thomas

CORPORATE SOURCE: Org. Chem. Inst., Univ. Muenster, Muenster, D-4400, Fed. Rep. Ger.

SOURCE: Chemische Berichte (1980), 113(8), 2739-48





CODEN: CHBEAM; ISSN: 0009-2940

DOCUMENT TYPE: Journal

LANGUAGE: German

OTHER SOURCE(S): CASREACT 93:186317

GI



AB Reaction of 1,3-Br₂C₆H₄ with BuLi, then pyrimidine, gave 44% pyrimidine I (R = Br) which reacted with 3-BrC₆H₄Li to give 65% diphenylpyrimidine II (R₁ = Br). Lithiating this gave 54% II (R₁ = Li) which cyclized with CuCl₂ to give 11% tetraazahexaphenylene III (X = CH) in an overall yield of 3.2%. Successively treating I (R = Br) with pyrimidine and BuLi gave 16% bispyrimidine IV which was cyclized with LiN(CHMe₂)₂ to give 1% octazahexaphenylene III (X = N) in an overall yield of 0.13%. In contrast to hexa-m-phenylene, III (X = CH) is planar, because of less Pitzer strain in the outer sphere of III (X = CH). Nitrating III (X = CH) gave its 4'',4''''',6',6''''-tetranitro derivative

IT 75307-73-2P 75307-74-3P


RL: SPN (Synthetic preparation); PREP (Preparation)

10/513699

(preparation of)


RN 75307-73-2 CAPLUS

CN Pyrimidine, 4-(3-chlorophenyl)-6-[3'-(6-phenyl-4-pyrimidinyl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 75307-74-3 CAPLUS

CN Pyrimidine, 4,4'-[1,1'-biphenyl]-3,3'-diylbis[6-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



L29 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:34951 CAPLUS

DOCUMENT NUMBER: 92:34951

ORIGINAL REFERENCE NO.: 92:5771a,5774a

TITLE: Correlation analysis of pyrimidine folic acid antagonists as antibacterial agents. I

AUTHOR(S): Coats, Eugene A.; Genther, Clara S.; Smith, Carl C.

CORPORATE SOURCE: Coll. Pharm., Univ. Cincinnati, Cincinnati, OH, 45267, USA

SOURCE: European Journal of Medicinal Chemistry (1979), 14(3), 261-70

CODEN: EJMCA5; ISSN: 0009-4374

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The activities of 175 pyrimidines as inhibitors of *Streptococcus faecium*, *Lactobacillus casei*, and *Pediococcus cerevisiae* are reported. In addition, the mode of action according to the ability of folic acid [59-30-3] or folinic acid [58-05-9] to reverse the inhibitory effect of the pyrimidines was determined. The 2,4-diamino substituent pattern appeared to be the dominant but not the sole factor controlling mode of action. Quant. structure-activity relations using regression anal., substituent consts., and indicator variables were developed in an effort to delineate influences on potency and to quant. differences between the test systems. Although aromatic and(or) lipophilic substituents at the 5 position of 2,4-diaminopyrimidines enhanced folate reversible inhibition against all 3 systems the derived equations quant. establish differences in and limitations on the extent of this effect.

IT 71525-23-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activity of, structure in relation to)

RN 71525-23-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[1,1'-biphenyl]-3-yl-5-(4-phenylbutyl)- (CA INDEX NAME)



10/513699

=>

=>

---Logging off of STN---

Connection closed by remote host
END

Unable to generate the STN prompt.
Exiting the script...